uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q34.585 | Q34 | What are the names of the genes that are targeted by the drug Carbamazepine in the treatment of Seizure? | In the context of Seizure, the drug Carbamazepine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seizure%" OR LOWER(efo_term) LIKE "%seizure%") AND (LOWER(drugName) LIKE "%carbamazepine%" OR LOWER(tradeNames_list) LIKE "%carbamazepine%" OR LOWER(syns_list) LIKE "%carbamazepine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_632192', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632228', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632240', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632252', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632276', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632288', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632300', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632324', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632336', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632348', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632360', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632384', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632396', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632408', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632420', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632432', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632444', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632456', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632468', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632480', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632492', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632516', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632528', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632540', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632552', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632564', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632588', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632600', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632612', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632624', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632636', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632648', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632660', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632672', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632684', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632696', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632708', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632720', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632732', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632744', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632756', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632768', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632780', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632792', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632804', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632816', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632828', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632840', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632852', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632864', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632876', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632900', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632912', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632924', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632936', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632948', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632960', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632984', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632996', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_633008', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_633020', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_633032', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_633044', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_633056', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_633068', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_633080', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_633092', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_633104', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_633116', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_633128', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_633140', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_633152', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_633164', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_633176', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_633188', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_633200', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_633212', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_633224', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_633236', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_633248', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_633260', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_633272', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_633284', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_633296', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_633308', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_633320', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632888', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632504', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632312', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632216', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632168', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632144', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632132', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632972', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632576', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632372', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632264', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632204', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632180', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632156', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.708 | Q34 | What are the names of the genes that are targeted by the drug Nilotinib Hydrochloride Monohydrate in the treatment of chronic myelogenous leukemia? | In the context of chronic myelogenous leukemia, the drug Nilotinib Hydrochloride Monohydrate targets the gene ABL proto-oncogene 1, non-receptor tyrosine kinase and BCR activator of RhoGEF and GTPase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic myelogenous leukemia%" OR LOWER(efo_term) LIKE "%chronic myelogenous leukemia%") AND (LOWER(drugName) LIKE "%nilotinib hydrochloride monohydrate%" OR LOWER(tradeNames_list) LIKE "%nilotinib hydrochloride monohydrate%" OR LOWER(syns_list) LIKE "%nilotinib hydrochloride monohydrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_745306', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745318', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745322', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745326', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745334', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745338', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745342', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745350', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745354', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745358', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745362', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745370', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745374', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745378', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745382', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745386', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745390', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745394', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745398', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745402', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745406', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745414', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745418', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745422', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745426', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745430', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745438', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745442', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745446', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745450', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745454', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745458', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745462', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745466', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745470', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745474', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745478', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745482', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745486', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745490', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745494', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745498', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745502', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745506', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745510', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745514', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745518', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745522', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745526', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745530', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745534', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745542', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745546', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745550', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745554', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745558', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745562', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745570', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745574', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745578', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745582', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745586', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745590', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745594', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745598', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745602', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745606', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745610', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745614', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745618', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745622', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745626', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745630', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745634', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745638', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745642', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745646', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745650', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745654', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745658', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745662', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745666', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745670', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_745674', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_745678', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_745682', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_745538', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745410', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745346', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745314', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745298', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745290', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745286', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745566', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745434', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745366', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745330', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745310', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745302', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745294', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'tradeNames_list': "['Tasigna']", 'syns_list': "['Nilotinib (as hydrochloride)', 'Nilotinib Hydrochloride MonohydrateNilotinib hydrochloride', 'Nilotinib hydrochloride anhydrousNilotinib hydrochloride hydrate', 'Nilotinib hydrochloride monohydrate']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1221 | Q34 | What are the names of the genes that are targeted by the drug Indacaterol Maleate in the treatment of emphysema? | In the context of emphysema, the drug Indacaterol Maleate targets the gene adrenoceptor beta 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%emphysema%" OR LOWER(efo_term) LIKE "%emphysema%") AND (LOWER(drugName) LIKE "%indacaterol maleate%" OR LOWER(tradeNames_list) LIKE "%indacaterol maleate%" OR LOWER(syns_list) LIKE "%indacaterol maleate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937188', 'drugName': 'Indacaterol Maleate', 'tradeNames_list': "['Arcapta neohaler', 'Onbrez breezhaler']", 'syns_list': "['Indacaterol (as maleate)', 'Indacaterol maleate', 'Indacterol maleateQAB-149-AFA', 'QAB149-AFA']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937192', 'drugName': 'Indacaterol Maleate', 'tradeNames_list': "['Arcapta neohaler', 'Onbrez breezhaler']", 'syns_list': "['Indacaterol (as maleate)', 'Indacaterol maleate', 'Indacterol maleateQAB-149-AFA', 'QAB149-AFA']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1306 | Q34 | What are the names of the genes that are targeted by the drug Nitroglycerin in the treatment of myocardial infarction? | In the context of myocardial infarction, the drug Nitroglycerin targets the gene guanylate cyclase 1 soluble subunit beta 1, guanylate cyclase 1 soluble subunit beta 2 (pseudogene), guanylate cyclase 1 soluble subunit alpha 2 and guanylate cyclase 1 soluble subunit alpha 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myocardial infarction%" OR LOWER(efo_term) LIKE "%myocardial infarction%") AND (LOWER(drugName) LIKE "%nitroglycerin%" OR LOWER(tradeNames_list) LIKE "%nitroglycerin%" OR LOWER(syns_list) LIKE "%nitroglycerin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_972647', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972715', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972579', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972511', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972477', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972681', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972613', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972545', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1651 | Q34 | What are the names of the genes that are targeted by the drug Abiraterone Acetate in the treatment of cancer? | In the context of cancer, the drug Abiraterone Acetate targets the gene cytochrome P450 family 17 subfamily A member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%abiraterone acetate%" OR LOWER(tradeNames_list) LIKE "%abiraterone acetate%" OR LOWER(syns_list) LIKE "%abiraterone acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094284', 'drugName': 'Abiraterone Acetate', 'tradeNames_list': "['Yonsa', 'Zytiga']", 'syns_list': "['Abiraterone acetate', 'CB-7630', 'CB7630', 'NSC-748121', 'NSC-749227']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CYP17A1', 'approvedName': 'cytochrome P450 family 17 subfamily A member 1'}, {'UUID': 'DrugTargetsIndication121923_text_1094301', 'drugName': 'Abiraterone Acetate', 'tradeNames_list': "['Yonsa', 'Zytiga']", 'syns_list': "['Abiraterone acetate', 'CB-7630', 'CB7630', 'NSC-748121', 'NSC-749227']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'CYP17A1', 'approvedName': 'cytochrome P450 family 17 subfamily A member 1'}, {'UUID': 'DrugTargetsIndication121923_text_1094288', 'drugName': 'Abiraterone Acetate', 'tradeNames_list': "['Yonsa', 'Zytiga']", 'syns_list': "['Abiraterone acetate', 'CB-7630', 'CB7630', 'NSC-748121', 'NSC-749227']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'CYP17A1', 'approvedName': 'cytochrome P450 family 17 subfamily A member 1'}, {'UUID': 'DrugTargetsIndication121923_text_1094296', 'drugName': 'Abiraterone Acetate', 'tradeNames_list': "['Yonsa', 'Zytiga']", 'syns_list': "['Abiraterone acetate', 'CB-7630', 'CB7630', 'NSC-748121', 'NSC-749227']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'CYP17A1', 'approvedName': 'cytochrome P450 family 17 subfamily A member 1'}, {'UUID': 'DrugTargetsIndication121923_text_1094297', 'drugName': 'Abiraterone Acetate', 'tradeNames_list': "['Yonsa', 'Zytiga']", 'syns_list': "['Abiraterone acetate', 'CB-7630', 'CB7630', 'NSC-748121', 'NSC-749227']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CYP17A1', 'approvedName': 'cytochrome P450 family 17 subfamily A member 1'}, {'UUID': 'DrugTargetsIndication121923_text_1094283', 'drugName': 'Abiraterone Acetate', 'tradeNames_list': "['Yonsa', 'Zytiga']", 'syns_list': "['Abiraterone acetate', 'CB-7630', 'CB7630', 'NSC-748121', 'NSC-749227']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'CYP17A1', 'approvedName': 'cytochrome P450 family 17 subfamily A member 1'}, {'UUID': 'DrugTargetsIndication121923_text_1094282', 'drugName': 'Abiraterone Acetate', 'tradeNames_list': "['Yonsa', 'Zytiga']", 'syns_list': "['Abiraterone acetate', 'CB-7630', 'CB7630', 'NSC-748121', 'NSC-749227']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CYP17A1', 'approvedName': 'cytochrome P450 family 17 subfamily A member 1'}, {'UUID': 'DrugTargetsIndication121923_text_1094295', 'drugName': 'Abiraterone Acetate', 'tradeNames_list': "['Yonsa', 'Zytiga']", 'syns_list': "['Abiraterone acetate', 'CB-7630', 'CB7630', 'NSC-748121', 'NSC-749227']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CYP17A1', 'approvedName': 'cytochrome P450 family 17 subfamily A member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1271 | Q34 | What are the names of the genes that are targeted by the drug Megestrol Acetate in the treatment of AIDS? | In the context of AIDS, the drug Megestrol Acetate targets the gene progesterone receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%aids%" OR LOWER(efo_term) LIKE "%aids%") AND (LOWER(drugName) LIKE "%megestrol acetate%" OR LOWER(tradeNames_list) LIKE "%megestrol acetate%" OR LOWER(syns_list) LIKE "%megestrol acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_940578', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acquired Immunodeficiency Syndrome', 'efo_term': 'AIDS', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940515', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acquired Immunodeficiency Syndrome', 'efo_term': 'AIDS', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940536', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acquired Immunodeficiency Syndrome', 'efo_term': 'AIDS', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940599', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acquired Immunodeficiency Syndrome', 'efo_term': 'AIDS', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940557', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acquired Immunodeficiency Syndrome', 'efo_term': 'AIDS', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.491 | Q34 | What are the names of the genes that are targeted by the drug Bupropion Hydrochloride in the treatment of major depressive disorder? | In the context of major depressive disorder, the drug Bupropion Hydrochloride targets the gene solute carrier family 6 member 2 and solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%major depressive disorder%" OR LOWER(efo_term) LIKE "%major depressive disorder%") AND (LOWER(drugName) LIKE "%bupropion hydrochloride%" OR LOWER(tradeNames_list) LIKE "%bupropion hydrochloride%" OR LOWER(syns_list) LIKE "%bupropion hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_434125', 'drugName': 'Bupropion Hydrochloride', 'tradeNames_list': "['Bupropion hydrochloride', 'Forfivo xl', 'Wellbutrin', 'Wellbutrin 100Wellbutrin 75', 'Wellbutrin sr', 'Wellbutrin xl', 'Zyban']", 'syns_list': "['Amfebutamone hydrochloride', 'BW 323', 'BW-323', 'BW323', 'Bupropion HClBupropion hcl', 'Bupropion hydrochloride', 'Mysimba', 'NSC-315851']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434141', 'drugName': 'Bupropion Hydrochloride', 'tradeNames_list': "['Bupropion hydrochloride', 'Forfivo xl', 'Wellbutrin', 'Wellbutrin 100Wellbutrin 75', 'Wellbutrin sr', 'Wellbutrin xl', 'Zyban']", 'syns_list': "['Amfebutamone hydrochloride', 'BW 323', 'BW-323', 'BW323', 'Bupropion HClBupropion hcl', 'Bupropion hydrochloride', 'Mysimba', 'NSC-315851']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.563 | Q34 | What are the names of the genes that are targeted by the drug Lidocaine in the treatment of Muscle spasm? | In the context of Muscle spasm, the drug Lidocaine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%muscle spasm%" OR LOWER(efo_term) LIKE "%muscle spasm%") AND (LOWER(drugName) LIKE "%lidocaine%" OR LOWER(tradeNames_list) LIKE "%lidocaine%" OR LOWER(syns_list) LIKE "%lidocaine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_638352', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638697', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638812', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638927', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639157', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639272', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639387', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639617', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639732', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639847', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639962', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640192', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640307', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640422', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640537', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640652', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640767', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640882', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640997', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641112', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641227', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641457', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641572', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641687', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641802', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641917', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642147', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642262', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642377', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642492', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642607', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642722', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642837', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642952', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643067', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643182', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643297', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643412', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643527', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643642', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643757', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643872', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643987', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644102', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644217', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644332', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644447', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644562', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_641342', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639502', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638582', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638122', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637892', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637777', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_642032', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_640077', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639042', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638467', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638237', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638007', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1149 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of colorectal adenocarcinoma? | Trametinib has not been approved by the FDA as a treatment for colorectal adenocarcinoma, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%colorectal adenocarcinoma%" OR LOWER(efo_term) LIKE "%colorectal adenocarcinoma%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_928697', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928817', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928857', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928897', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928977', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929017', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929057', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929137', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929177', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929217', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929257', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929337', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929377', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929417', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929457', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929497', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929537', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929577', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929617', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929657', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929697', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929777', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929817', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929857', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929897', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929937', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930017', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930057', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930097', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930137', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930177', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930217', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930257', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930297', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930337', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930377', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930417', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930457', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930497', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930537', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930577', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930617', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930657', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930697', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930737', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930777', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930817', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930857', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930897', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930937', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930977', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931057', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931097', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931137', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931177', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931217', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931257', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931337', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931377', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931417', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931457', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931497', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931537', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931577', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931617', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931657', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931697', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931737', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931777', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931817', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931857', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931897', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931937', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931977', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932017', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932057', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932097', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932137', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932177', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932217', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932257', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932297', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932337', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932377', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932417', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932457', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931017', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929737', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929097', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928777', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928617', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928537', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928497', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_931297', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929977', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929297', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928937', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928737', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928657', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928577', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1127 | Q34 | What are the names of the genes that are targeted by the drug Cobimetinib Fumarate in the treatment of metastatic melanoma? | In the context of metastatic melanoma, the drug Cobimetinib Fumarate targets the gene mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%metastatic melanoma%" OR LOWER(efo_term) LIKE "%metastatic melanoma%") AND (LOWER(drugName) LIKE "%cobimetinib fumarate%" OR LOWER(tradeNames_list) LIKE "%cobimetinib fumarate%" OR LOWER(syns_list) LIKE "%cobimetinib fumarate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_927155', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927158', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927159', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927160', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927162', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927163', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927164', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927166', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927167', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927168', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927169', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927171', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927172', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927173', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927165', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927157', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927153', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927151', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927150', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927170', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927161', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927156', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927154', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927152', 'drugName': 'Cobimetinib Fumarate', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarateXl-518 hemifumarate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.807 | Q34 | What are the names of the genes that are targeted by the drug Pitolisant Hydrochloride in the treatment of hypersomnia? | In the context of hypersomnia, the drug Pitolisant Hydrochloride targets the gene histamine receptor H3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypersomnia%" OR LOWER(efo_term) LIKE "%hypersomnia%") AND (LOWER(drugName) LIKE "%pitolisant hydrochloride%" OR LOWER(tradeNames_list) LIKE "%pitolisant hydrochloride%" OR LOWER(syns_list) LIKE "%pitolisant hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828133', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'syns_list': "['Ciproxidine', 'Pitolisant hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Disorders of Excessive Somnolence', 'efo_term': 'hypersomnia', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3'}, {'UUID': 'DrugTargetsIndication121923_text_828139', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'syns_list': "['Ciproxidine', 'Pitolisant hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Disorders of Excessive Somnolence', 'efo_term': 'hypersomnia', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3'}, {'UUID': 'DrugTargetsIndication121923_text_828141', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'syns_list': "['Ciproxidine', 'Pitolisant hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Disorders of Excessive Somnolence', 'efo_term': 'hypersomnia', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3'}, {'UUID': 'DrugTargetsIndication121923_text_828137', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'syns_list': "['Ciproxidine', 'Pitolisant hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Disorders of Excessive Somnolence', 'efo_term': 'hypersomnia', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3'}, {'UUID': 'DrugTargetsIndication121923_text_828125', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'syns_list': "['Ciproxidine', 'Pitolisant hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Disorders of Excessive Somnolence', 'efo_term': 'hypersomnia', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3'}, {'UUID': 'DrugTargetsIndication121923_text_828123', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'syns_list': "['Ciproxidine', 'Pitolisant hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Disorders of Excessive Somnolence', 'efo_term': 'hypersomnia', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3'}, {'UUID': 'DrugTargetsIndication121923_text_828129', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'syns_list': "['Ciproxidine', 'Pitolisant hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Disorders of Excessive Somnolence', 'efo_term': 'hypersomnia', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3'}, {'UUID': 'DrugTargetsIndication121923_text_828135', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'syns_list': "['Ciproxidine', 'Pitolisant hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Disorders of Excessive Somnolence', 'efo_term': 'hypersomnia', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3'}, {'UUID': 'DrugTargetsIndication121923_text_828131', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'syns_list': "['Ciproxidine', 'Pitolisant hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Disorders of Excessive Somnolence', 'efo_term': 'hypersomnia', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3'}, {'UUID': 'DrugTargetsIndication121923_text_828127', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'syns_list': "['Ciproxidine', 'Pitolisant hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Disorders of Excessive Somnolence', 'efo_term': 'hypersomnia', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.516 | Q34 | What are the names of the genes that are targeted by the drug Amantadine Hydrochloride in the treatment of Parkinson disease? | In the context of Parkinson disease, the drug Amantadine Hydrochloride targets the gene glutamate ionotropic receptor NMDA type subunit 1, glutamate ionotropic receptor NMDA type subunit 2A, glutamate ionotropic receptor NMDA type subunit 2B, glutamate ionotropic receptor NMDA type subunit 2D, glutamate ionotropic receptor NMDA type subunit 3B, glutamate ionotropic receptor NMDA type subunit 2C and glutamate ionotropic receptor NMDA type subunit 3A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%parkinson disease%" OR LOWER(efo_term) LIKE "%parkinson disease%") AND (LOWER(drugName) LIKE "%amantadine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%amantadine hydrochloride%" OR LOWER(syns_list) LIKE "%amantadine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_441038', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441052', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441064', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441065', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441078', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441079', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441080', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441093', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441094', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441106', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441107', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441120', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441121', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441122', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441134', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441135', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441136', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441148', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441149', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441150', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441162', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441164', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441176', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441177', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441178', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441190', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441192', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441204', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441205', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441206', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441218', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441219', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441220', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441232', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441233', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441234', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441246', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441247', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441248', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441260', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441261', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441262', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441274', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441275', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441276', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441288', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441289', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441290', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441302', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441303', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441304', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441317', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441318', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441330', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441331', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441332', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441344', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441346', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441358', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441359', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441360', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441372', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441373', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441374', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441386', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441387', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441388', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441400', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441401', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441402', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441414', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441415', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441416', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441428', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441429', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441430', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441442', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441443', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441444', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441456', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441457', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441458', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441470', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441471', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441472', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441484', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441316', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441163', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441092', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441051', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441036', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441023', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441022', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441345', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441191', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441108', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441066', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441050', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Secondary', 'efo_term': 'secondary Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441037', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441024', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.638 | Q34 | What are the names of the genes that are targeted by the drug Axitinib in the treatment of papillary renal cell carcinoma? | In the context of papillary renal cell carcinoma, the drug Axitinib targets the gene kinase insert domain receptor, fms related receptor tyrosine kinase 1 and fms related receptor tyrosine kinase 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%papillary renal cell carcinoma%" OR LOWER(efo_term) LIKE "%papillary renal cell carcinoma%") AND (LOWER(drugName) LIKE "%axitinib%" OR LOWER(tradeNames_list) LIKE "%axitinib%" OR LOWER(syns_list) LIKE "%axitinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_689366', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689492', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689534', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689576', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689660', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689702', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689744', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689828', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689870', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689912', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689954', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690038', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690080', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690122', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689786', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689450', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689282', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689198', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689156', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689996', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689618', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689408', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689324', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689240', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1465 | Q34 | What are the names of the genes that are targeted by the drug Tazarotene in the treatment of Genetic hypopigmentation of the skin? | In the context of Genetic hypopigmentation of the skin, the drug Tazarotene targets the gene retinoic acid receptor gamma, retinoic acid receptor beta and retinoic acid receptor alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%genetic hypopigmentation of the skin%" OR LOWER(efo_term) LIKE "%genetic hypopigmentation of the skin%") AND (LOWER(drugName) LIKE "%tazarotene%" OR LOWER(tradeNames_list) LIKE "%tazarotene%" OR LOWER(syns_list) LIKE "%tazarotene%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1055503', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055527', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055535', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055543', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055519', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055487', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055471', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055463', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055551', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055511', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055495', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055479', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1771 | Q34 | What are the names of the genes that are targeted by the drug Alendronate Sodium in the treatment of metabolic disease? | In the context of metabolic disease, the drug Alendronate Sodium targets the gene farnesyl diphosphate synthase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%metabolic disease%" OR LOWER(efo_term) LIKE "%metabolic disease%") AND (LOWER(drugName) LIKE "%alendronate sodium%" OR LOWER(tradeNames_list) LIKE "%alendronate sodium%" OR LOWER(syns_list) LIKE "%alendronate sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1099489', 'drugName': 'Alendronate Sodium', 'tradeNames_list': "['Alendronate sodium', 'Binosto', 'Fosamax']", 'syns_list': "['Adrovance', 'Alendronate (as sodium)', 'Alendronate sodiumAlendronate sodium hydrate', 'Alendronate sodium trihydrateAlendronic acid monosodium salt trihydrate', 'Fosavance', 'G-704,650G-704650', 'MK-217', 'NSC-722597', 'NSC-758931', 'Sodium alendronateSodium alendronate trihydrate', 'Vantavo']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'metabolic disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099496', 'drugName': 'Alendronate Sodium', 'tradeNames_list': "['Alendronate sodium', 'Binosto', 'Fosamax']", 'syns_list': "['Adrovance', 'Alendronate (as sodium)', 'Alendronate sodiumAlendronate sodium hydrate', 'Alendronate sodium trihydrateAlendronic acid monosodium salt trihydrate', 'Fosavance', 'G-704,650G-704650', 'MK-217', 'NSC-722597', 'NSC-758931', 'Sodium alendronateSodium alendronate trihydrate', 'Vantavo']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'metabolic disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099503', 'drugName': 'Alendronate Sodium', 'tradeNames_list': "['Alendronate sodium', 'Binosto', 'Fosamax']", 'syns_list': "['Adrovance', 'Alendronate (as sodium)', 'Alendronate sodiumAlendronate sodium hydrate', 'Alendronate sodium trihydrateAlendronic acid monosodium salt trihydrate', 'Fosavance', 'G-704,650G-704650', 'MK-217', 'NSC-722597', 'NSC-758931', 'Sodium alendronateSodium alendronate trihydrate', 'Vantavo']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'metabolic disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1531 | Q34 | What are the names of the genes that are targeted by the drug Rolapitant Hydrochloride in the treatment of Chemotherapy-induced nausea and vomiting? | In the context of Chemotherapy-induced nausea and vomiting, the drug Rolapitant Hydrochloride targets the gene tachykinin receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chemotherapy-induced nausea and vomiting%" OR LOWER(efo_term) LIKE "%chemotherapy-induced nausea and vomiting%") AND (LOWER(drugName) LIKE "%rolapitant hydrochloride%" OR LOWER(tradeNames_list) LIKE "%rolapitant hydrochloride%" OR LOWER(syns_list) LIKE "%rolapitant hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1073115', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073120', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073121', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073123', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073126', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073127', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073129', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073132', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073133', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073135', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073136', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073139', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073141', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073142', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073144', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073145', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073147', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073148', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073150', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073151', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073130', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073118', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073112', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073109', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073108', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073138', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073124', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073117', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073114', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073111', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_list': "['Varubi']", 'syns_list': "['Rolapitant hcl h20', 'Rolapitant hydrochlorideRolapitant hydrochloride monohydrate', 'SCH-619734', 'SCH619734']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1159 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of breast cancer? | Trametinib has not been approved by the FDA as a treatment for breast cancer, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%breast cancer%" OR LOWER(efo_term) LIKE "%breast cancer%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_928707', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928827', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928867', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928907', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928987', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929027', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929067', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929147', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929187', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929227', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929267', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929347', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929387', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929427', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929467', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929507', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929547', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929587', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929627', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929667', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929707', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929787', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929827', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929867', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929907', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929947', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930027', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930067', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930107', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930147', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930187', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930227', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930267', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930307', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930347', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930387', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930427', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930467', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930507', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930547', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930587', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930627', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930667', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930707', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930747', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930787', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930827', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930867', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930907', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930947', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930987', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931067', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931107', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931147', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931187', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931227', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931267', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931347', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931387', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931427', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931467', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931507', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931547', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931587', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931627', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931667', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931707', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931747', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931787', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931827', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931867', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931907', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931947', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931987', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932027', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932067', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932107', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932147', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932187', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932227', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932267', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932307', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932347', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932387', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932427', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932467', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931027', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929747', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929107', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928787', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928627', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928547', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928507', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_931307', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929987', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929307', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928947', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928747', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928667', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928587', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.796 | Q34 | What are the names of the genes that are targeted by the drug Calcifediol in the treatment of secondary hyperparathyroidism? | In the context of secondary hyperparathyroidism, the drug Calcifediol targets the gene vitamin D receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%secondary hyperparathyroidism%" OR LOWER(efo_term) LIKE "%secondary hyperparathyroidism%") AND (LOWER(drugName) LIKE "%calcifediol%" OR LOWER(tradeNames_list) LIKE "%calcifediol%" OR LOWER(syns_list) LIKE "%calcifediol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_823428', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823452', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823460', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823468', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823484', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823492', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823500', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823516', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823524', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823532', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823508', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823412', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823396', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823388', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823444', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823476', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823436', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823420', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823404', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.118 | Q34 | What are the names of the genes that are targeted by the drug Escitalopram Oxalate in the treatment of generalized anxiety disorder? | In the context of generalized anxiety disorder, the drug Escitalopram Oxalate targets the gene solute carrier family 6 member 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%generalized anxiety disorder%" OR LOWER(efo_term) LIKE "%generalized anxiety disorder%") AND (LOWER(drugName) LIKE "%escitalopram oxalate%" OR LOWER(tradeNames_list) LIKE "%escitalopram oxalate%" OR LOWER(syns_list) LIKE "%escitalopram oxalate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_206549', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206576', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206585', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206594', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206567', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206531', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206513', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206504', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206603', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206558', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206540', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206522', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'generalized anxiety disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.745 | Q34 | What are the names of the genes that are targeted by the drug Buprenorphine in the treatment of drug dependence? | In the context of drug dependence, the drug Buprenorphine targets the gene opioid receptor mu 1 and opioid receptor kappa 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%drug dependence%" OR LOWER(efo_term) LIKE "%drug dependence%") AND (LOWER(drugName) LIKE "%buprenorphine%" OR LOWER(tradeNames_list) LIKE "%buprenorphine%" OR LOWER(syns_list) LIKE "%buprenorphine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_764504', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764420', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765540', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764336', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764392', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764728', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764448', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765512', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764532', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764560', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765148', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765260', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764168', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764672', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765316', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764756', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764084', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764280', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764812', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764868', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764896', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764952', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764980', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765008', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765036', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765064', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765120', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766268', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765176', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765204', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765232', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766492', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764644', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766464', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764056', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765428', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764112', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764476', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764784', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765484', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764364', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765596', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765372', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764308', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765624', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765652', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765680', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765708', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765736', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765764', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765792', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765848', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765876', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765904', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765932', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765960', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765988', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766044', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766072', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766100', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766128', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766156', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766184', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766212', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766240', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765400', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766296', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766324', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766352', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766380', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766408', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766436', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765568', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764196', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766520', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766548', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765288', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764700', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765820', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764924', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764588', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764252', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764140', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765456', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764840', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766016', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765092', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764616', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765344', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764224', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766552', 'drugName': 'Buprenorphine Hydrochloride', 'tradeNames_list': "['Belbuca', 'Buprenex', 'Buprenorphine hydrochloride', 'Espranor', 'GabupNatzon', 'Prefibin', 'Probuphine', 'Subutex']", 'syns_list': "['Anorfin', 'Buprederm', 'Buprenorphine hcl', 'Buprenorphine hydrochlorideBuprenorphine hydrochloride ciii', 'Buprex', 'CL 112,302', 'CL-112302Finibron', 'Lepetan', 'M-6029', 'NIH 8805', 'NIH-8805', 'NopanRX 6029-M HCL', 'RX-6029-M HCL', 'SCH-028444', 'UM 952', 'UM-952Vetergesic']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766554', 'drugName': 'Buprenorphine Hydrochloride', 'tradeNames_list': "['Belbuca', 'Buprenex', 'Buprenorphine hydrochloride', 'Espranor', 'GabupNatzon', 'Prefibin', 'Probuphine', 'Subutex']", 'syns_list': "['Anorfin', 'Buprederm', 'Buprenorphine hcl', 'Buprenorphine hydrochlorideBuprenorphine hydrochloride ciii', 'Buprex', 'CL 112,302', 'CL-112302Finibron', 'Lepetan', 'M-6029', 'NIH 8805', 'NIH-8805', 'NopanRX 6029-M HCL', 'RX-6029-M HCL', 'SCH-028444', 'UM 952', 'UM-952Vetergesic']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766556', 'drugName': 'Buprenorphine Hydrochloride', 'tradeNames_list': "['Belbuca', 'Buprenex', 'Buprenorphine hydrochloride', 'Espranor', 'GabupNatzon', 'Prefibin', 'Probuphine', 'Subutex']", 'syns_list': "['Anorfin', 'Buprederm', 'Buprenorphine hcl', 'Buprenorphine hydrochlorideBuprenorphine hydrochloride ciii', 'Buprex', 'CL 112,302', 'CL-112302Finibron', 'Lepetan', 'M-6029', 'NIH 8805', 'NIH-8805', 'NopanRX 6029-M HCL', 'RX-6029-M HCL', 'SCH-028444', 'UM 952', 'UM-952Vetergesic']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766558', 'drugName': 'Buprenorphine Hydrochloride', 'tradeNames_list': "['Belbuca', 'Buprenex', 'Buprenorphine hydrochloride', 'Espranor', 'GabupNatzon', 'Prefibin', 'Probuphine', 'Subutex']", 'syns_list': "['Anorfin', 'Buprederm', 'Buprenorphine hcl', 'Buprenorphine hydrochlorideBuprenorphine hydrochloride ciii', 'Buprex', 'CL 112,302', 'CL-112302Finibron', 'Lepetan', 'M-6029', 'NIH 8805', 'NIH-8805', 'NopanRX 6029-M HCL', 'RX-6029-M HCL', 'SCH-028444', 'UM 952', 'UM-952Vetergesic']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766560', 'drugName': 'Buprenorphine Hydrochloride', 'tradeNames_list': "['Belbuca', 'Buprenex', 'Buprenorphine hydrochloride', 'Espranor', 'GabupNatzon', 'Prefibin', 'Probuphine', 'Subutex']", 'syns_list': "['Anorfin', 'Buprederm', 'Buprenorphine hcl', 'Buprenorphine hydrochlorideBuprenorphine hydrochloride ciii', 'Buprex', 'CL 112,302', 'CL-112302Finibron', 'Lepetan', 'M-6029', 'NIH 8805', 'NIH-8805', 'NopanRX 6029-M HCL', 'RX-6029-M HCL', 'SCH-028444', 'UM 952', 'UM-952Vetergesic']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766562', 'drugName': 'Buprenorphine Hydrochloride', 'tradeNames_list': "['Belbuca', 'Buprenex', 'Buprenorphine hydrochloride', 'Espranor', 'GabupNatzon', 'Prefibin', 'Probuphine', 'Subutex']", 'syns_list': "['Anorfin', 'Buprederm', 'Buprenorphine hcl', 'Buprenorphine hydrochlorideBuprenorphine hydrochloride ciii', 'Buprex', 'CL 112,302', 'CL-112302Finibron', 'Lepetan', 'M-6029', 'NIH 8805', 'NIH-8805', 'NopanRX 6029-M HCL', 'RX-6029-M HCL', 'SCH-028444', 'UM 952', 'UM-952Vetergesic']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766564', 'drugName': 'Buprenorphine Hydrochloride', 'tradeNames_list': "['Belbuca', 'Buprenex', 'Buprenorphine hydrochloride', 'Espranor', 'GabupNatzon', 'Prefibin', 'Probuphine', 'Subutex']", 'syns_list': "['Anorfin', 'Buprederm', 'Buprenorphine hcl', 'Buprenorphine hydrochlorideBuprenorphine hydrochloride ciii', 'Buprex', 'CL 112,302', 'CL-112302Finibron', 'Lepetan', 'M-6029', 'NIH 8805', 'NIH-8805', 'NopanRX 6029-M HCL', 'RX-6029-M HCL', 'SCH-028444', 'UM 952', 'UM-952Vetergesic']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766566', 'drugName': 'Buprenorphine Hydrochloride', 'tradeNames_list': "['Belbuca', 'Buprenex', 'Buprenorphine hydrochloride', 'Espranor', 'GabupNatzon', 'Prefibin', 'Probuphine', 'Subutex']", 'syns_list': "['Anorfin', 'Buprederm', 'Buprenorphine hcl', 'Buprenorphine hydrochlorideBuprenorphine hydrochloride ciii', 'Buprex', 'CL 112,302', 'CL-112302Finibron', 'Lepetan', 'M-6029', 'NIH 8805', 'NIH-8805', 'NopanRX 6029-M HCL', 'RX-6029-M HCL', 'SCH-028444', 'UM 952', 'UM-952Vetergesic']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766568', 'drugName': 'Buprenorphine Hydrochloride', 'tradeNames_list': "['Belbuca', 'Buprenex', 'Buprenorphine hydrochloride', 'Espranor', 'GabupNatzon', 'Prefibin', 'Probuphine', 'Subutex']", 'syns_list': "['Anorfin', 'Buprederm', 'Buprenorphine hcl', 'Buprenorphine hydrochlorideBuprenorphine hydrochloride ciii', 'Buprex', 'CL 112,302', 'CL-112302Finibron', 'Lepetan', 'M-6029', 'NIH 8805', 'NIH-8805', 'NopanRX 6029-M HCL', 'RX-6029-M HCL', 'SCH-028444', 'UM 952', 'UM-952Vetergesic']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766570', 'drugName': 'Buprenorphine Hydrochloride', 'tradeNames_list': "['Belbuca', 'Buprenex', 'Buprenorphine hydrochloride', 'Espranor', 'GabupNatzon', 'Prefibin', 'Probuphine', 'Subutex']", 'syns_list': "['Anorfin', 'Buprederm', 'Buprenorphine hcl', 'Buprenorphine hydrochlorideBuprenorphine hydrochloride ciii', 'Buprex', 'CL 112,302', 'CL-112302Finibron', 'Lepetan', 'M-6029', 'NIH 8805', 'NIH-8805', 'NopanRX 6029-M HCL', 'RX-6029-M HCL', 'SCH-028444', 'UM 952', 'UM-952Vetergesic']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1709 | Q34 | What are the names of the genes that are targeted by the drug Degarelix in the treatment of neoplasm? | In the context of neoplasm, the drug Degarelix targets the gene gonadotropin releasing hormone receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%degarelix%" OR LOWER(tradeNames_list) LIKE "%degarelix%" OR LOWER(syns_list) LIKE "%degarelix%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097157', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097144', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097281', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097143', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097147', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097148', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097131', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097140', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097152', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097141', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097136', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097185', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097127', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097269', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097125', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097257', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097156', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097173', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097149', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097161', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097132', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097245', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097133', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097129', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097159', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097123', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097155', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097153', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097233', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097160', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097135', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097151', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097124', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097209', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097145', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097137', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097139', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097197', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097221', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097128', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097231', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097240', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097264', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097244', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097169', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097171', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097252', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097195', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097255', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097256', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097243', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097180', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097172', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097168', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097181', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097184', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097183', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097192', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097232', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097265', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097196', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097204', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097241', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097193', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097207', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097208', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097280', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097229', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097216', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097267', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097253', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097205', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097268', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097217', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097219', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097279', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097220', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097276', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097277', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097228', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097225', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097226', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097142', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097165', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097237', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097238', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097249', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097250', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097166', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097134', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097146', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097177', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097178', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097261', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097262', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097189', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097150', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097190', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097201', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097202', 'drugName': 'Degarelix', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix', 'FE200486 (AS ACETATE SALT)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1088 | Q34 | What are the names of the genes that are targeted by the drug Apalutamide in the treatment of neoplasm? | In the context of neoplasm, the drug Apalutamide targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%apalutamide%" OR LOWER(tradeNames_list) LIKE "%apalutamide%" OR LOWER(syns_list) LIKE "%apalutamide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_921897', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921848', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921876', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921846', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921850', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921851', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921860', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921852', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921923', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921853', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921932', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921892', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921856', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921963', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921857', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921872', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921858', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921859', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921906', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921870', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921878', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921880', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921881', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921882', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921956', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921863', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921887', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921959', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921866', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921890', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921891', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921941', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921868', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921869', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921896', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921953', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921898', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921871', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921900', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921901', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921902', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921862', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921888', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921877', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921907', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921908', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921909', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921910', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921911', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921912', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921913', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921916', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921917', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921918', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921919', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921920', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921921', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921957', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921883', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921926', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921927', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921928', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921929', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921930', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921931', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921961', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921933', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921889', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921936', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921937', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921938', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921939', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921940', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921960', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921942', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921943', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921893', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921946', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921947', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921948', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921949', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921952', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921951', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921962', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921958', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921899', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921879', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921861', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921873', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921903', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921922', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921886', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921867', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921950', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921847', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921849', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921945', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921875', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921905', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921955', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.836 | Q34 | What are the names of the genes that are targeted by the drug Acetaminophen in the treatment of migraine disorder? | In the context of migraine disorder, the drug Acetaminophen targets the gene prostaglandin-endoperoxide synthase 2, prostaglandin-endoperoxide synthase 1, transient receptor potential cation channel subfamily V member 1 and fatty acid amide hydrolase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%migraine disorder%" OR LOWER(efo_term) LIKE "%migraine disorder%") AND (LOWER(drugName) LIKE "%acetaminophen%" OR LOWER(tradeNames_list) LIKE "%acetaminophen%" OR LOWER(syns_list) LIKE "%acetaminophen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_829268', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829583', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829688', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829793', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830003', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830108', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830213', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830423', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830528', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830633', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830738', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830948', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831053', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831158', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831263', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831368', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831473', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831578', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831683', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831788', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831893', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832103', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832208', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832313', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832418', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832523', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832733', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832838', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_831998', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_830318', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829478', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829058', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828848', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828743', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832628', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_830843', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829898', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829373', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829163', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828953', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.121 | Q34 | What are the names of the genes that are targeted by the drug Desvenlafaxine in the treatment of major depressive disorder? | In the context of major depressive disorder, the drug Desvenlafaxine targets the gene solute carrier family 6 member 4 and solute carrier family 6 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%major depressive disorder%" OR LOWER(efo_term) LIKE "%major depressive disorder%") AND (LOWER(drugName) LIKE "%desvenlafaxine%" OR LOWER(tradeNames_list) LIKE "%desvenlafaxine%" OR LOWER(syns_list) LIKE "%desvenlafaxine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_206639', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206657', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206663', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206669', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206681', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206687', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206693', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206705', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206711', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206719', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206726', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206740', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206747', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206754', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206761', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206768', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206775', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206782', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206789', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206796', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206803', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206817', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206824', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206831', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206838', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206810', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206651', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206627', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206615', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206609', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206699', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206733', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206675', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206645', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206633', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206621', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.661 | Q34 | What are the names of the genes that are targeted by the drug Tolvaptan in the treatment of heart failure? | In the context of heart failure, the drug Tolvaptan targets the gene arginine vasopressin receptor 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%heart failure%" OR LOWER(efo_term) LIKE "%heart failure%") AND (LOWER(drugName) LIKE "%tolvaptan%" OR LOWER(tradeNames_list) LIKE "%tolvaptan%" OR LOWER(syns_list) LIKE "%tolvaptan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_695126', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695155', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695156', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695170', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695185', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695186', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695200', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695215', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695216', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695230', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695231', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695246', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695260', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695261', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695275', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695276', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695290', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695291', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695305', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695306', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695320', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695321', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695201', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695141', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695111', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695096', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695095', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695245', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695171', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695140', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695125', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695110', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1889 | Q34 | What are the names of the genes that are targeted by the drug Cinacalcet in the treatment of parathyroid disease? | In the context of parathyroid disease, the drug Cinacalcet targets the gene calcium sensing receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%parathyroid disease%" OR LOWER(efo_term) LIKE "%parathyroid disease%") AND (LOWER(drugName) LIKE "%cinacalcet%" OR LOWER(tradeNames_list) LIKE "%cinacalcet%" OR LOWER(syns_list) LIKE "%cinacalcet%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149085', 'drugName': 'Cinacalcet', 'tradeNames_list': "['Sensipar']", 'syns_list': "['AMG 073', 'AMG-073', 'AMG073', 'Cinacalcet', 'KRN-1493', 'KRN1493']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149053', 'drugName': 'Cinacalcet', 'tradeNames_list': "['Sensipar']", 'syns_list': "['AMG 073', 'AMG-073', 'AMG073', 'Cinacalcet', 'KRN-1493', 'KRN1493']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149045', 'drugName': 'Cinacalcet', 'tradeNames_list': "['Sensipar']", 'syns_list': "['AMG 073', 'AMG-073', 'AMG073', 'Cinacalcet', 'KRN-1493', 'KRN1493']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149069', 'drugName': 'Cinacalcet', 'tradeNames_list': "['Sensipar']", 'syns_list': "['AMG 073', 'AMG-073', 'AMG073', 'Cinacalcet', 'KRN-1493', 'KRN1493']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149077', 'drugName': 'Cinacalcet', 'tradeNames_list': "['Sensipar']", 'syns_list': "['AMG 073', 'AMG-073', 'AMG073', 'Cinacalcet', 'KRN-1493', 'KRN1493']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149061', 'drugName': 'Cinacalcet', 'tradeNames_list': "['Sensipar']", 'syns_list': "['AMG 073', 'AMG-073', 'AMG073', 'Cinacalcet', 'KRN-1493', 'KRN1493']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.640 | Q34 | What are the names of the genes that are targeted by the drug Axitinib in the treatment of renal carcinoma? | In the context of renal carcinoma, the drug Axitinib targets the gene kinase insert domain receptor, fms related receptor tyrosine kinase 1 and fms related receptor tyrosine kinase 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%renal carcinoma%" OR LOWER(efo_term) LIKE "%renal carcinoma%") AND (LOWER(drugName) LIKE "%axitinib%" OR LOWER(tradeNames_list) LIKE "%axitinib%" OR LOWER(syns_list) LIKE "%axitinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_689242', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689322', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689326', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689364', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689406', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689410', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689448', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689490', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689494', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689532', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689536', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689578', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689616', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689620', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689658', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689662', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689700', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689704', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689742', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689746', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689784', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689826', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689830', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689868', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689872', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689910', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689952', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689956', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689994', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689998', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690036', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690040', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690078', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690082', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690120', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690124', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689788', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689452', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689284', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689200', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689158', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689154', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689914', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689574', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689368', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689280', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689238', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689196', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.371 | Q34 | What are the names of the genes that are targeted by the drug Hydrocortisone in the treatment of inflammation? | In the context of inflammation, the drug Hydrocortisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%inflammation%" OR LOWER(efo_term) LIKE "%inflammation%") AND (LOWER(drugName) LIKE "%hydrocortisone%" OR LOWER(tradeNames_list) LIKE "%hydrocortisone%" OR LOWER(syns_list) LIKE "%hydrocortisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_241717', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240815', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240810', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240979', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241056', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240897', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241307', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241302', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241553', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241389', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241061', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241712', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241466', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241630', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241471', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241138', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241220', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241384', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241635', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241794', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241876', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241881', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241799', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240892', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241143', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241548', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240974', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241225', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218729', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220185', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217481', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218105', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218937', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220601', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219145', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218313', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219353', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219561', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217689', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217897', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218521', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219769', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219977', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220393', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.270 | Q34 | What are the names of the genes that are targeted by the drug Loteprednol Etabonate in the treatment of eye inflammation? | In the context of eye inflammation, the drug Loteprednol Etabonate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%eye inflammation%" OR LOWER(efo_term) LIKE "%eye inflammation%") AND (LOWER(drugName) LIKE "%loteprednol etabonate%" OR LOWER(tradeNames_list) LIKE "%loteprednol etabonate%" OR LOWER(syns_list) LIKE "%loteprednol etabonate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_225454', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225478', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225486', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225494', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225510', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225518', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225526', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225542', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225550', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225558', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225566', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225582', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225590', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225598', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225606', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225534', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225470', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225438', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225422', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225414', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225574', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225502', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225462', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225446', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225430', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'syns_list': "['CDDD 5604', 'CDDD-5604', 'HGP-1', 'KPI-121', 'LoteprednolLoteprednol etabonate', 'P-5604']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.660 | Q34 | What are the names of the genes that are targeted by the drug Tolvaptan in the treatment of congestive heart failure? | In the context of congestive heart failure, the drug Tolvaptan targets the gene arginine vasopressin receptor 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%congestive heart failure%" OR LOWER(efo_term) LIKE "%congestive heart failure%") AND (LOWER(drugName) LIKE "%tolvaptan%" OR LOWER(tradeNames_list) LIKE "%tolvaptan%" OR LOWER(syns_list) LIKE "%tolvaptan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_695170', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695215', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695230', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695245', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695275', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695290', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695305', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695320', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695200', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695140', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695110', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695095', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695260', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695185', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695155', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695125', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.942 | Q34 | What are the names of the genes that are targeted by the drug Ibuprofen in the treatment of pharyngitis? | In the context of pharyngitis, the drug Ibuprofen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pharyngitis%" OR LOWER(efo_term) LIKE "%pharyngitis%") AND (LOWER(drugName) LIKE "%ibuprofen%" OR LOWER(tradeNames_list) LIKE "%ibuprofen%" OR LOWER(syns_list) LIKE "%ibuprofen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_840173', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840410', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840489', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840568', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840726', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840805', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840884', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841042', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841121', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841200', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841279', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841437', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841516', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841595', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841674', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841753', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840963', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840331', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840015', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839857', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839778', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841358', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840647', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840252', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840094', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839936', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.828 | Q34 | What are the names of the genes that are targeted by the drug Acetaminophen in the treatment of Dysmenorrhea? | In the context of Dysmenorrhea, the drug Acetaminophen targets the gene prostaglandin-endoperoxide synthase 2, prostaglandin-endoperoxide synthase 1, transient receptor potential cation channel subfamily V member 1 and fatty acid amide hydrolase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%dysmenorrhea%" OR LOWER(efo_term) LIKE "%dysmenorrhea%") AND (LOWER(drugName) LIKE "%acetaminophen%" OR LOWER(tradeNames_list) LIKE "%acetaminophen%" OR LOWER(syns_list) LIKE "%acetaminophen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_829259', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829574', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829679', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829784', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829994', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830099', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830204', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830414', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830519', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830624', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830729', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830939', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831044', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831149', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831254', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831359', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831464', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831569', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831674', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831779', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831884', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832094', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832199', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832304', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832409', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832514', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832724', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832829', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_831989', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_830309', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829469', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829049', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828839', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828734', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832619', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_830834', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829889', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829364', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829154', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828944', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.872 | Q34 | What are the names of the genes that are targeted by the drug Aspirin in the treatment of migraine disorder? | In the context of migraine disorder, the drug Aspirin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%migraine disorder%" OR LOWER(efo_term) LIKE "%migraine disorder%") AND (LOWER(drugName) LIKE "%aspirin%" OR LOWER(tradeNames_list) LIKE "%aspirin%" OR LOWER(syns_list) LIKE "%aspirin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_834442', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834913', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835070', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835227', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835541', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835698', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835855', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836012', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834756', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834128', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833814', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833657', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835384', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834599', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834285', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833971', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.47 | Q34 | What are the names of the genes that are targeted by the drug Aripiprazole in the treatment of schizophrenia? | In the context of schizophrenia, the drug Aripiprazole targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 2A and 5-hydroxytryptamine receptor 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%schizophrenia%" OR LOWER(efo_term) LIKE "%schizophrenia%") AND (LOWER(drugName) LIKE "%aripiprazole%" OR LOWER(tradeNames_list) LIKE "%aripiprazole%" OR LOWER(syns_list) LIKE "%aripiprazole%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_158031', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158049', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158055', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158061', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158073', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158079', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158085', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158097', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158103', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158109', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158115', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158127', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158133', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158139', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158145', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158151', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158157', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158163', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158169', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158175', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158181', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158193', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158199', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158205', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158211', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158217', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158229', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158235', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158241', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158247', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158253', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158259', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158265', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158271', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158277', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158283', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158289', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158295', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158301', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158307', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158313', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158319', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158325', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158331', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158337', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158343', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158349', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158355', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158361', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158367', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158373', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158385', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158391', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158397', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158403', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158409', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158415', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158427', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158433', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158439', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158445', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158451', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158457', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158463', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158469', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158475', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158481', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158487', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158493', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158499', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158505', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158511', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158517', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158523', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158529', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158535', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158541', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158547', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158553', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158559', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158565', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158571', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158577', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158583', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158589', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158595', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158379', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158187', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158091', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158043', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158019', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158007', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158001', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158421', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158223', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158121', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158067', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158037', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158025', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158013', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1384 | Q34 | What are the names of the genes that are targeted by the drug Clonidine in the treatment of neuropathic pain? | In the context of neuropathic pain, the drug Clonidine targets the gene adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neuropathic pain%" OR LOWER(efo_term) LIKE "%neuropathic pain%") AND (LOWER(drugName) LIKE "%clonidine%" OR LOWER(tradeNames_list) LIKE "%clonidine%" OR LOWER(syns_list) LIKE "%clonidine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1033832', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1033937', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1033972', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034007', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1033902', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1033762', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1033692', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1033657', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034042', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1033867', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1033797', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1033727', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1694 | Q34 | What are the names of the genes that are targeted by the drug Relugolix in the treatment of prostate cancer? | In the context of prostate cancer, the drug Relugolix targets the gene gonadotropin releasing hormone receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%prostate cancer%" OR LOWER(efo_term) LIKE "%prostate cancer%") AND (LOWER(drugName) LIKE "%relugolix%" OR LOWER(tradeNames_list) LIKE "%relugolix%" OR LOWER(syns_list) LIKE "%relugolix%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1096979', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096963', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096944', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096968', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096955', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096987', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096960', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096971', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096984', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096947', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096976', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096952', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096967', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096959', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096943', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096951', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096983', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096975', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.998 | Q34 | What are the names of the genes that are targeted by the drug Umeclidinium Bromide in the treatment of chronic obstructive pulmonary disease? | In the context of chronic obstructive pulmonary disease, the drug Umeclidinium Bromide targets the gene cholinergic receptor muscarinic 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic obstructive pulmonary disease%" OR LOWER(efo_term) LIKE "%chronic obstructive pulmonary disease%") AND (LOWER(drugName) LIKE "%umeclidinium bromide%" OR LOWER(tradeNames_list) LIKE "%umeclidinium bromide%" OR LOWER(syns_list) LIKE "%umeclidinium bromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857415', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857430', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857435', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857425', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857395', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857390', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857405', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857420', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857410', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857400', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.882 | Q34 | What are the names of the genes that are targeted by the drug Diclofenac in the treatment of actinic keratosis? | In the context of actinic keratosis, the drug Diclofenac targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%actinic keratosis%" OR LOWER(efo_term) LIKE "%actinic keratosis%") AND (LOWER(drugName) LIKE "%diclofenac%" OR LOWER(tradeNames_list) LIKE "%diclofenac%" OR LOWER(syns_list) LIKE "%diclofenac%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_837518', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836978', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837188', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837998', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837098', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837908', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837488', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837878', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837428', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837608', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837398', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837968', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837308', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837068', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837758', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837578', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837668', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837698', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837338', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837158', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837368', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837938', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837008', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837818', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837638', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837248', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837848', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837548', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838028', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837788', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837278', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837038', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837728', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837458', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837128', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837218', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836404', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836800', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836818', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836836', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836854', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836062', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836224', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836440', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836872', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836890', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836458', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836908', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836926', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836116', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836944', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836242', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836422', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836026', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836476', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836494', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836206', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836134', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836296', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836260', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836602', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836314', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836620', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836512', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836530', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836170', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836332', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836656', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836674', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836350', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836692', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836710', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836638', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836098', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836188', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836368', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836728', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836584', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836152', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836080', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836044', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836746', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836386', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836764', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836782', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836278', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836548', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836566', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.779 | Q34 | What are the names of the genes that are targeted by the drug Niraparib in the treatment of cancer? | In the context of cancer, the drug Niraparib targets the gene poly(ADP-ribose) polymerase 2 and poly(ADP-ribose) polymerase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%niraparib%" OR LOWER(tradeNames_list) LIKE "%niraparib%" OR LOWER(syns_list) LIKE "%niraparib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_793614', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793534', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793334', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793574', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793494', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793654', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793414', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793374', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793734', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793774', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793694', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793454', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793731', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793651', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793533', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793491', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793453', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793773', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793732', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793772', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793771', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793730', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hereditary Breast and Ovarian Cancer Syndrome', 'efo_term': 'Hereditary breast and ovarian cancer syndrome', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793691', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793531', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793331', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793493', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793653', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793373', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793372', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793692', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793370', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hereditary Breast and Ovarian Cancer Syndrome', 'efo_term': 'Hereditary breast and ovarian cancer syndrome', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793532', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793573', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793451', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793570', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hereditary Breast and Ovarian Cancer Syndrome', 'efo_term': 'Hereditary breast and ovarian cancer syndrome', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793410', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hereditary Breast and Ovarian Cancer Syndrome', 'efo_term': 'Hereditary breast and ovarian cancer syndrome', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793613', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793571', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793452', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793612', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793411', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793610', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hereditary Breast and Ovarian Cancer Syndrome', 'efo_term': 'Hereditary breast and ovarian cancer syndrome', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793413', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793572', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793650', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hereditary Breast and Ovarian Cancer Syndrome', 'efo_term': 'Hereditary breast and ovarian cancer syndrome', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793652', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793492', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793611', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793490', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hereditary Breast and Ovarian Cancer Syndrome', 'efo_term': 'Hereditary breast and ovarian cancer syndrome', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793371', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793330', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hereditary Breast and Ovarian Cancer Syndrome', 'efo_term': 'Hereditary breast and ovarian cancer syndrome', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793693', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793770', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hereditary Breast and Ovarian Cancer Syndrome', 'efo_term': 'Hereditary breast and ovarian cancer syndrome', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793733', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793690', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hereditary Breast and Ovarian Cancer Syndrome', 'efo_term': 'Hereditary breast and ovarian cancer syndrome', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793333', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793332', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793450', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hereditary Breast and Ovarian Cancer Syndrome', 'efo_term': 'Hereditary breast and ovarian cancer syndrome', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793412', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793530', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hereditary Breast and Ovarian Cancer Syndrome', 'efo_term': 'Hereditary breast and ovarian cancer syndrome', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793722', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793483', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793385', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793602', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793401', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793601', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793465', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793323', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793625', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793403', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793521', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793522', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793523', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793681', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793682', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793683', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793345', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793361', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793643', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793642', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793563', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793362', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793545', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793561', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793363', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793505', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793562', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793665', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793425', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793441', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793402', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793305', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793442', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793745', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793443', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793705', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793721', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793321', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793723', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793481', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1228 | Q34 | What are the names of the genes that are targeted by the drug Ribavirin in the treatment of cirrhosis of liver? | In the context of cirrhosis of liver, the drug Ribavirin targets the gene inosine monophosphate dehydrogenase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cirrhosis of liver%" OR LOWER(efo_term) LIKE "%cirrhosis of liver%") AND (LOWER(drugName) LIKE "%ribavirin%" OR LOWER(tradeNames_list) LIKE "%ribavirin%" OR LOWER(syns_list) LIKE "%ribavirin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937565', 'drugName': 'Ribavirin', 'tradeNames_list': "['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'RibavirinRibofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']", 'syns_list': "['Cotronak', 'NSC-163039', 'Ribavirin', 'Ribavirin biopartnersRibavirin mylan', 'Ribavirin teva', 'SCH 18908', 'SCH-18908', 'Tribavirin']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver', 'approvedSymbol': 'IMPDH1', 'approvedName': 'inosine monophosphate dehydrogenase 1'}, {'UUID': 'DrugTargetsIndication121923_text_937564', 'drugName': 'Ribavirin', 'tradeNames_list': "['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'RibavirinRibofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']", 'syns_list': "['Cotronak', 'NSC-163039', 'Ribavirin', 'Ribavirin biopartnersRibavirin mylan', 'Ribavirin teva', 'SCH 18908', 'SCH-18908', 'Tribavirin']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis', 'efo_term': 'cirrhosis of liver', 'approvedSymbol': 'IMPDH1', 'approvedName': 'inosine monophosphate dehydrogenase 1'}, {'UUID': 'DrugTargetsIndication121923_text_937590', 'drugName': 'Ribavirin', 'tradeNames_list': "['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'RibavirinRibofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']", 'syns_list': "['Cotronak', 'NSC-163039', 'Ribavirin', 'Ribavirin biopartnersRibavirin mylan', 'Ribavirin teva', 'SCH 18908', 'SCH-18908', 'Tribavirin']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver', 'approvedSymbol': 'IMPDH1', 'approvedName': 'inosine monophosphate dehydrogenase 1'}, {'UUID': 'DrugTargetsIndication121923_text_937589', 'drugName': 'Ribavirin', 'tradeNames_list': "['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'RibavirinRibofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']", 'syns_list': "['Cotronak', 'NSC-163039', 'Ribavirin', 'Ribavirin biopartnersRibavirin mylan', 'Ribavirin teva', 'SCH 18908', 'SCH-18908', 'Tribavirin']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis', 'efo_term': 'cirrhosis of liver', 'approvedSymbol': 'IMPDH1', 'approvedName': 'inosine monophosphate dehydrogenase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1982 | Q34 | What are the names of the genes that are targeted by the drug Selinexor in the treatment of multiple myeloma? | In the context of multiple myeloma, the drug Selinexor targets the gene exportin 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%multiple myeloma%" OR LOWER(efo_term) LIKE "%multiple myeloma%") AND (LOWER(drugName) LIKE "%selinexor%" OR LOWER(tradeNames_list) LIKE "%selinexor%" OR LOWER(syns_list) LIKE "%selinexor%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193930', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194056', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194098', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194140', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194224', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194266', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194308', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194392', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194434', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194476', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194518', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194602', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194644', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194686', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194728', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194770', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194812', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194854', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194896', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194938', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194980', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195064', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195106', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195148', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195190', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195232', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195316', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195358', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195400', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195442', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195484', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195526', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195568', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195610', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195652', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195694', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195022', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194350', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194014', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193846', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193762', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193720', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195274', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194560', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194182', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193972', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193888', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193804', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.5 | Q34 | What are the names of the genes that are targeted by the drug Loxapine in the treatment of bipolar I disorder? | In the context of bipolar I disorder, the drug Loxapine targets the gene 5-hydroxytryptamine receptor 2C, dopamine receptor D2, dopamine receptor D3, dopamine receptor D4 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bipolar i disorder%" OR LOWER(efo_term) LIKE "%bipolar i disorder%") AND (LOWER(drugName) LIKE "%loxapine%" OR LOWER(tradeNames_list) LIKE "%loxapine%" OR LOWER(syns_list) LIKE "%loxapine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_149113', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149149', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149161', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149173', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149197', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149209', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149221', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_149245', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_149257', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_149269', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_149281', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_149305', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_149317', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_149329', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_149341', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_149353', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_149365', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_149377', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_149389', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_149401', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_149413', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_149437', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_149449', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_149461', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_149425', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_149233', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_149089', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149065', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149053', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149137', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149293', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_149185', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149125', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149101', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149077', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1010 | Q34 | What are the names of the genes that are targeted by the drug Ipratropium Bromide in the treatment of chronic obstructive pulmonary disease? | In the context of chronic obstructive pulmonary disease, the drug Ipratropium Bromide targets the gene cholinergic receptor muscarinic 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic obstructive pulmonary disease%" OR LOWER(efo_term) LIKE "%chronic obstructive pulmonary disease%") AND (LOWER(drugName) LIKE "%ipratropium bromide%" OR LOWER(tradeNames_list) LIKE "%ipratropium bromide%" OR LOWER(syns_list) LIKE "%ipratropium bromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857476', 'drugName': 'Ipratropium Bromide', 'tradeNames_list': "['Atrovent', 'Atrovent aerocaps', 'Atrovent fte', 'Atrovent hfaAtrovent udvs', 'Ipratrop', 'Ipratrop steripoule', 'Ipratropium bromideRespontin', 'Rinatec', 'Tropiovent']", 'syns_list': "['Ipratropium bromide', 'Ipratropium bromide anhydrousIpratropium bromide hydrate', 'Ipratropium bromide monohydrateNSC-759613', 'SCH 1000-BR-MONOHYDRATE', 'SCH-1000-BR-']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1707 | Q34 | What are the names of the genes that are targeted by the drug Degarelix Acetate in the treatment of prostate adenocarcinoma? | In the context of prostate adenocarcinoma, the drug Degarelix Acetate targets the gene gonadotropin releasing hormone receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%prostate adenocarcinoma%" OR LOWER(efo_term) LIKE "%prostate adenocarcinoma%") AND (LOWER(drugName) LIKE "%degarelix acetate%" OR LOWER(tradeNames_list) LIKE "%degarelix acetate%" OR LOWER(syns_list) LIKE "%degarelix acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097143', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097155', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097159', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097151', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097127', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097123', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097135', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097147', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097139', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097131', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.265 | Q34 | What are the names of the genes that are targeted by the drug Budesonide in the treatment of allergic rhinitis? | In the context of allergic rhinitis, the drug Budesonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic rhinitis%" OR LOWER(efo_term) LIKE "%allergic rhinitis%") AND (LOWER(drugName) LIKE "%budesonide%" OR LOWER(tradeNames_list) LIKE "%budesonide%" OR LOWER(syns_list) LIKE "%budesonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222481', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222570', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222571', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222615', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222660', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222661', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222705', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222750', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222751', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222795', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222796', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222841', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222885', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222886', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222930', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222931', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222975', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222976', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223020', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223021', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223065', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223110', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223111', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223155', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223156', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223200', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223245', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223246', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223290', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223291', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223335', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223336', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223380', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223381', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223425', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223426', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223470', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223471', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223515', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223516', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223560', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223561', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223605', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223606', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223650', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223651', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223695', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223696', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223740', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223741', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223785', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223830', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223831', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223875', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223876', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223920', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223921', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223966', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224010', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224011', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224055', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224056', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224100', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224101', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224145', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224146', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224190', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224191', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224235', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224236', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224280', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224281', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224325', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224326', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224370', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224371', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224415', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224416', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224460', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224461', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224505', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224506', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224550', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224551', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224595', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224596', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223786', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223066', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222706', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222526', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222436', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222391', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222390', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223965', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223201', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222840', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222616', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222525', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222480', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222435', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1555 | Q34 | What are the names of the genes that are targeted by the drug Vorinostat in the treatment of T-cell non-Hodgkin lymphoma? | In the context of T-cell non-Hodgkin lymphoma, the drug Vorinostat targets the gene histone deacetylase 1, histone deacetylase 3, histone deacetylase 6 and histone deacetylase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%t-cell non-hodgkin lymphoma%" OR LOWER(efo_term) LIKE "%t-cell non-hodgkin lymphoma%") AND (LOWER(drugName) LIKE "%vorinostat%" OR LOWER(tradeNames_list) LIKE "%vorinostat%" OR LOWER(syns_list) LIKE "%vorinostat%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1077140', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077404', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077492', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077580', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077756', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077844', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077932', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078108', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078196', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078284', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078372', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078548', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078636', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078724', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078812', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078900', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078988', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1079076', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079164', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079252', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079340', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079516', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079604', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079692', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079780', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079428', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1077316', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076964', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076788', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076700', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1078020', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078460', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1077668', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077228', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077052', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076876', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell', 'efo_term': 'T-cell non-Hodgkin lymphoma', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1814 | Q34 | What are the names of the genes that are targeted by the drug Montelukast in the treatment of Airway obstruction? | In the context of Airway obstruction, the drug Montelukast targets the gene cysteinyl leukotriene receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%airway obstruction%" OR LOWER(efo_term) LIKE "%airway obstruction%") AND (LOWER(drugName) LIKE "%montelukast%" OR LOWER(tradeNames_list) LIKE "%montelukast%" OR LOWER(syns_list) LIKE "%montelukast%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100422', 'drugName': 'Montelukast', 'tradeNames_list': "['Singulair']", 'syns_list': "['Brondilat', 'MK-476', 'Montelukast']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CYSLTR1', 'approvedName': 'cysteinyl leukotriene receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.447 | Q34 | What are the names of the genes that are targeted by the drug Epinephrine in the treatment of allergic rhinitis? | In the context of allergic rhinitis, the drug Epinephrine targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D, adrenoceptor alpha 1B, adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic rhinitis%" OR LOWER(efo_term) LIKE "%allergic rhinitis%") AND (LOWER(drugName) LIKE "%epinephrine%" OR LOWER(tradeNames_list) LIKE "%epinephrine%" OR LOWER(syns_list) LIKE "%epinephrine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_360935', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361037', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361041', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361090', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361143', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361147', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361196', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361249', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361253', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361302', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361306', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361359', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361408', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361412', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361461', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361465', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361514', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361518', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361567', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361571', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361620', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361673', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361677', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361726', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361730', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361779', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361832', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361836', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361885', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361889', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361938', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361942', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361991', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361995', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362044', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362048', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362097', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362101', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362150', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362154', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362203', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362207', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362256', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362260', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362309', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362313', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362362', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362366', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362415', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362419', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362468', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362521', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362525', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362574', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362578', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362627', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362631', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362684', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362733', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362737', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362786', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362790', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362839', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362843', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362892', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362896', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362945', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362949', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362998', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363002', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363051', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363055', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363104', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363108', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363157', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363161', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363210', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363214', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363263', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363267', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363316', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363320', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363369', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363373', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363422', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363426', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362472', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361624', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361200', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360988', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360882', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360829', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360825', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362680', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361783', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361355', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361094', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360984', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360931', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360878', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1009 | Q34 | What are the names of the genes that are targeted by the drug Ipratropium Bromide in the treatment of atopic eczema? | In the context of atopic eczema, the drug Ipratropium Bromide targets the gene cholinergic receptor muscarinic 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%atopic eczema%" OR LOWER(efo_term) LIKE "%atopic eczema%") AND (LOWER(drugName) LIKE "%ipratropium bromide%" OR LOWER(tradeNames_list) LIKE "%ipratropium bromide%" OR LOWER(syns_list) LIKE "%ipratropium bromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857475', 'drugName': 'Ipratropium Bromide', 'tradeNames_list': "['Atrovent', 'Atrovent aerocaps', 'Atrovent fte', 'Atrovent hfaAtrovent udvs', 'Ipratrop', 'Ipratrop steripoule', 'Ipratropium bromideRespontin', 'Rinatec', 'Tropiovent']", 'syns_list': "['Ipratropium bromide', 'Ipratropium bromide anhydrousIpratropium bromide hydrate', 'Ipratropium bromide monohydrateNSC-759613', 'SCH 1000-BR-MONOHYDRATE', 'SCH-1000-BR-']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1084 | Q34 | What are the names of the genes that are targeted by the drug Testosterone Enanthate in the treatment of Hypogonadotropic hypogonadism? | In the context of Hypogonadotropic hypogonadism, the drug Testosterone Enanthate targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypogonadotropic hypogonadism%" OR LOWER(efo_term) LIKE "%hypogonadotropic hypogonadism%") AND (LOWER(drugName) LIKE "%testosterone enanthate%" OR LOWER(tradeNames_list) LIKE "%testosterone enanthate%" OR LOWER(syns_list) LIKE "%testosterone enanthate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_921410', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921437', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921446', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921455', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921473', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921482', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921491', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921509', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921518', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921527', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921536', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921554', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921563', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921572', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921581', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921590', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921599', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921608', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921617', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921626', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921635', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921653', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921662', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921671', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921680', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921689', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921707', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921716', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921725', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921734', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921743', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921752', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921761', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921770', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921779', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921788', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921797', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921806', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921815', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921824', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921833', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921842', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921644', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921500', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921428', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921392', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921374', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921365', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921698', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921545', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921464', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921419', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921401', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921383', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.843 | Q34 | What are the names of the genes that are targeted by the drug Celecoxib in the treatment of rheumatoid arthritis? | In the context of rheumatoid arthritis, the drug Celecoxib targets the gene prostaglandin-endoperoxide synthase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rheumatoid arthritis%" OR LOWER(efo_term) LIKE "%rheumatoid arthritis%") AND (LOWER(drugName) LIKE "%celecoxib%" OR LOWER(tradeNames_list) LIKE "%celecoxib%" OR LOWER(syns_list) LIKE "%celecoxib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_833494', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833050', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832939', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833272', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833383', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833161', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1774 | Q34 | What are the names of the genes that are targeted by the drug Alendronate Sodium in the treatment of osteitis deformans? | In the context of osteitis deformans, the drug Alendronate Sodium targets the gene farnesyl diphosphate synthase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%osteitis deformans%" OR LOWER(efo_term) LIKE "%osteitis deformans%") AND (LOWER(drugName) LIKE "%alendronate sodium%" OR LOWER(tradeNames_list) LIKE "%alendronate sodium%" OR LOWER(syns_list) LIKE "%alendronate sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1099492', 'drugName': 'Alendronate Sodium', 'tradeNames_list': "['Alendronate sodium', 'Binosto', 'Fosamax']", 'syns_list': "['Adrovance', 'Alendronate (as sodium)', 'Alendronate sodiumAlendronate sodium hydrate', 'Alendronate sodium trihydrateAlendronic acid monosodium salt trihydrate', 'Fosavance', 'G-704,650G-704650', 'MK-217', 'NSC-722597', 'NSC-758931', 'Sodium alendronateSodium alendronate trihydrate', 'Vantavo']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099499', 'drugName': 'Alendronate Sodium', 'tradeNames_list': "['Alendronate sodium', 'Binosto', 'Fosamax']", 'syns_list': "['Adrovance', 'Alendronate (as sodium)', 'Alendronate sodiumAlendronate sodium hydrate', 'Alendronate sodium trihydrateAlendronic acid monosodium salt trihydrate', 'Fosavance', 'G-704,650G-704650', 'MK-217', 'NSC-722597', 'NSC-758931', 'Sodium alendronateSodium alendronate trihydrate', 'Vantavo']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099506', 'drugName': 'Alendronate Sodium', 'tradeNames_list': "['Alendronate sodium', 'Binosto', 'Fosamax']", 'syns_list': "['Adrovance', 'Alendronate (as sodium)', 'Alendronate sodiumAlendronate sodium hydrate', 'Alendronate sodium trihydrateAlendronic acid monosodium salt trihydrate', 'Fosavance', 'G-704,650G-704650', 'MK-217', 'NSC-722597', 'NSC-758931', 'Sodium alendronateSodium alendronate trihydrate', 'Vantavo']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.306 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of ankylosing spondylitis? | In the context of ankylosing spondylitis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ankylosing spondylitis%" OR LOWER(efo_term) LIKE "%ankylosing spondylitis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227761', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228616', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228901', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229186', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229756', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230041', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230326', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230896', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231181', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231466', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231751', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232321', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230611', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228331', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227191', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226621', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226336', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232036', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229471', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228046', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227476', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226906', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1376 | Q34 | What are the names of the genes that are targeted by the drug Setmelanotide Acetate in the treatment of obesity? | In the context of obesity, the drug Setmelanotide Acetate targets the gene melanocortin 4 receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%obesity%" OR LOWER(efo_term) LIKE "%obesity%") AND (LOWER(drugName) LIKE "%setmelanotide acetate%" OR LOWER(tradeNames_list) LIKE "%setmelanotide acetate%" OR LOWER(syns_list) LIKE "%setmelanotide acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1025293', 'drugName': 'Setmelanotide Acetate', 'tradeNames_list': "['Imcivree']", 'syns_list': "['Setmelanotide acetate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'MC4R', 'approvedName': 'melanocortin 4 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1025294', 'drugName': 'Setmelanotide Acetate', 'tradeNames_list': "['Imcivree']", 'syns_list': "['Setmelanotide acetate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'MC4R', 'approvedName': 'melanocortin 4 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1025295', 'drugName': 'Setmelanotide Acetate', 'tradeNames_list': "['Imcivree']", 'syns_list': "['Setmelanotide acetate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'MC4R', 'approvedName': 'melanocortin 4 receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1543 | Q34 | What are the names of the genes that are targeted by the drug Cannabidiol in the treatment of hamartoma? | In the context of hamartoma, the drug Cannabidiol targets the gene cannabinoid receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hamartoma%" OR LOWER(efo_term) LIKE "%hamartoma%") AND (LOWER(drugName) LIKE "%cannabidiol%" OR LOWER(tradeNames_list) LIKE "%cannabidiol%" OR LOWER(syns_list) LIKE "%cannabidiol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1073763', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073982', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074055', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074128', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074274', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074347', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074420', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074566', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074639', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074712', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074785', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074931', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075004', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075077', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075150', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075223', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075296', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075369', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075442', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075515', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075588', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075734', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075807', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075880', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075953', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076026', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076172', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076245', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076318', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075661', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074493', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073909', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073617', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073471', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073398', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076099', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074858', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074201', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073836', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073690', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073544', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.315 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of allergic rhinitis? | In the context of allergic rhinitis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic rhinitis%" OR LOWER(efo_term) LIKE "%allergic rhinitis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_226916', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227477', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227486', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227762', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228047', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228056', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228332', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228617', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228626', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228902', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228911', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229196', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229472', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229481', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229757', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229766', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230042', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230051', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230327', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230336', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230612', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230897', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230906', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231182', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231191', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231467', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231752', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231761', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232037', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232046', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232322', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232331', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230621', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228341', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227201', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226631', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226346', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226337', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231476', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229187', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227771', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227192', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226907', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226622', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.151 | Q34 | What are the names of the genes that are targeted by the drug Ciclesonide in the treatment of Airway obstruction? | In the context of Airway obstruction, the drug Ciclesonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%airway obstruction%" OR LOWER(efo_term) LIKE "%airway obstruction%") AND (LOWER(drugName) LIKE "%ciclesonide%" OR LOWER(tradeNames_list) LIKE "%ciclesonide%" OR LOWER(syns_list) LIKE "%ciclesonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217452', 'drugName': 'Ciclesonide', 'tradeNames_list': "['Alvesco', 'Alvesco 160', 'Alvesco 80', 'Omnaris', 'Zetonna']", 'syns_list': "['BI54903', 'Ciclesonide', 'RPR-251526', 'RPR251526']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217442', 'drugName': 'Ciclesonide', 'tradeNames_list': "['Alvesco', 'Alvesco 160', 'Alvesco 80', 'Omnaris', 'Zetonna']", 'syns_list': "['BI54903', 'Ciclesonide', 'RPR-251526', 'RPR251526']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217472', 'drugName': 'Ciclesonide', 'tradeNames_list': "['Alvesco', 'Alvesco 160', 'Alvesco 80', 'Omnaris', 'Zetonna']", 'syns_list': "['BI54903', 'Ciclesonide', 'RPR-251526', 'RPR251526']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217462', 'drugName': 'Ciclesonide', 'tradeNames_list': "['Alvesco', 'Alvesco 160', 'Alvesco 80', 'Omnaris', 'Zetonna']", 'syns_list': "['BI54903', 'Ciclesonide', 'RPR-251526', 'RPR251526']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1156 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of Erdheim-Chester disease? | Trametinib has not been approved by the FDA as a treatment for Erdheim-Chester disease, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%erdheim-chester disease%" OR LOWER(efo_term) LIKE "%erdheim-chester disease%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_927763', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927784', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927791', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927798', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927812', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927819', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927826', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927840', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927847', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927854', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927861', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927875', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927882', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927889', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927896', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927903', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927910', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927917', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927924', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927931', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927938', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927952', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927959', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927966', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927973', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927980', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927994', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928001', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928008', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928015', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928022', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928029', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928036', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928043', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928050', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928057', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928064', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928071', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928078', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928085', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928092', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928099', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928106', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928113', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928120', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928127', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928134', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928141', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928148', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928155', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928162', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928176', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928183', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928190', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928197', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928204', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928211', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928225', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928232', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928239', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928246', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928253', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928260', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928267', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928274', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928281', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928288', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928295', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928302', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928309', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928316', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928323', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928330', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928337', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928344', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928351', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928358', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928365', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928372', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928379', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928386', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928393', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928400', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928407', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928414', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928421', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928169', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927945', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927833', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927777', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927749', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927735', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927728', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928218', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927987', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927868', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927805', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927770', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927756', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927742', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Erdheim-Chester Disease', 'efo_term': 'Erdheim-Chester disease', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1222 | Q34 | What are the names of the genes that are targeted by the drug Indacaterol Maleate in the treatment of chronic bronchitis? | In the context of chronic bronchitis, the drug Indacaterol Maleate targets the gene adrenoceptor beta 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic bronchitis%" OR LOWER(efo_term) LIKE "%chronic bronchitis%") AND (LOWER(drugName) LIKE "%indacaterol maleate%" OR LOWER(tradeNames_list) LIKE "%indacaterol maleate%" OR LOWER(syns_list) LIKE "%indacaterol maleate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937189', 'drugName': 'Indacaterol Maleate', 'tradeNames_list': "['Arcapta neohaler', 'Onbrez breezhaler']", 'syns_list': "['Indacaterol (as maleate)', 'Indacaterol maleate', 'Indacterol maleateQAB-149-AFA', 'QAB149-AFA']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937193', 'drugName': 'Indacaterol Maleate', 'tradeNames_list': "['Arcapta neohaler', 'Onbrez breezhaler']", 'syns_list': "['Indacaterol (as maleate)', 'Indacaterol maleate', 'Indacterol maleateQAB-149-AFA', 'QAB149-AFA']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.578 | Q34 | What are the names of the genes that are targeted by the drug Lidocaine in the treatment of muscle cramp? | In the context of muscle cramp, the drug Lidocaine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%muscle cramp%" OR LOWER(efo_term) LIKE "%muscle cramp%") AND (LOWER(drugName) LIKE "%lidocaine%" OR LOWER(tradeNames_list) LIKE "%lidocaine%" OR LOWER(syns_list) LIKE "%lidocaine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_638023', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638237', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638253', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638352', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638467', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638483', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638582', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638697', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638713', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638812', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638828', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638943', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639042', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639058', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639157', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639173', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639272', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639288', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639387', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639403', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639502', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639617', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639633', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639732', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639748', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639847', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639962', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639978', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640077', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640093', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640192', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640208', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640307', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640323', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640422', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640438', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640537', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640553', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640652', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640668', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640767', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640783', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640882', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640898', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640997', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641013', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641112', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641128', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641227', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641243', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641342', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641457', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641473', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641572', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641588', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641687', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641703', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641818', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641917', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_641933', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642032', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642048', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642147', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642163', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642262', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642278', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642377', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642393', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642492', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642508', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642607', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642623', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642722', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642738', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642837', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642853', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642952', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642968', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643067', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643083', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643182', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643198', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643297', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643313', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643412', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643428', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_641358', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639518', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638598', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638138', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637908', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637793', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637777', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_641802', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639863', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_638927', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638368', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638122', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638007', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637892', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.51 | Q34 | What are the names of the genes that are targeted by the drug Asenapine Maleate in the treatment of bipolar I disorder? | In the context of bipolar I disorder, the drug Asenapine Maleate targets the gene dopamine receptor D2 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bipolar i disorder%" OR LOWER(efo_term) LIKE "%bipolar i disorder%") AND (LOWER(drugName) LIKE "%asenapine maleate%" OR LOWER(tradeNames_list) LIKE "%asenapine maleate%" OR LOWER(syns_list) LIKE "%asenapine maleate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_197590', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197608', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197614', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197620', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197632', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197638', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197644', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197656', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197662', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197668', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197674', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197686', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197692', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197698', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197704', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197710', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197716', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197722', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197728', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197734', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197740', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197752', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197758', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197764', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197770', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197776', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197788', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197794', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197800', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197806', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197746', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197650', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197602', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197578', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197566', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197560', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197782', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197680', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197626', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197596', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197584', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197572', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1538 | Q34 | What are the names of the genes that are targeted by the drug Dronabinol in the treatment of Anorexia? | In the context of Anorexia, the drug Dronabinol targets the gene cannabinoid receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%anorexia%" OR LOWER(efo_term) LIKE "%anorexia%") AND (LOWER(drugName) LIKE "%dronabinol%" OR LOWER(tradeNames_list) LIKE "%dronabinol%" OR LOWER(syns_list) LIKE "%dronabinol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1073326', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073218', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073254', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073290', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073285', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Anorexia Nervosa', 'efo_term': 'anorexia nervosa', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073249', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Anorexia Nervosa', 'efo_term': 'anorexia nervosa', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073213', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Anorexia Nervosa', 'efo_term': 'anorexia nervosa', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073321', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Anorexia Nervosa', 'efo_term': 'anorexia nervosa', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.731 | Q34 | What are the names of the genes that are targeted by the drug Dabrafenib in the treatment of cancer? | In the context of cancer, the drug Dabrafenib targets the gene B-Raf proto-oncogene, serine/threonine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%dabrafenib%" OR LOWER(tradeNames_list) LIKE "%dabrafenib%" OR LOWER(syns_list) LIKE "%dabrafenib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_752792', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753056', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752813', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752750', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752764', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753797', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752680', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753455', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752925', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752806', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753208', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752981', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752708', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753303', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753284', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752855', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752862', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752841', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752883', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753474', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753094', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752701', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753132', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752918', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752694', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753170', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752946', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753664', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752743', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753379', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753246', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753683', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752827', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752974', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752999', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753398', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753322', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752785', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752736', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752757', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753037', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752848', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753436', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753702', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752869', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752876', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753075', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753721', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752778', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752834', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752890', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753113', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752904', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752729', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753512', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752911', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753417', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753588', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752799', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753018', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752932', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753569', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753189', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753550', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753341', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753759', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752953', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752960', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753227', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753645', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752820', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753626', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752715', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753740', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753265', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753778', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753607', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753531', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753360', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752897', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752722', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753816', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752687', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753151', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752939', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752967', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753493', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752771', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753321', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753435', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753017', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753340', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753359', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753036', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753055', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753454', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753074', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753492', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753093', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753473', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.839 | Q34 | What are the names of the genes that are targeted by the drug Celecoxib in the treatment of Dysmenorrhea? | In the context of Dysmenorrhea, the drug Celecoxib targets the gene prostaglandin-endoperoxide synthase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%dysmenorrhea%" OR LOWER(efo_term) LIKE "%dysmenorrhea%") AND (LOWER(drugName) LIKE "%celecoxib%" OR LOWER(tradeNames_list) LIKE "%celecoxib%" OR LOWER(syns_list) LIKE "%celecoxib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_833490', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833046', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832935', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833268', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833379', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833157', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1388 | Q34 | What are the names of the genes that are targeted by the drug Brimonidine Tartrate in the treatment of hypertension? | In the context of hypertension, the drug Brimonidine Tartrate targets the gene adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypertension%" OR LOWER(efo_term) LIKE "%hypertension%") AND (LOWER(drugName) LIKE "%brimonidine tartrate%" OR LOWER(tradeNames_list) LIKE "%brimonidine tartrate%" OR LOWER(syns_list) LIKE "%brimonidine tartrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1034071', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034086', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034097', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034100', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034112', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034115', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034116', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034130', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034131', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034142', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034145', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034157', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034160', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034161', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034172', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034175', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034176', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034187', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034190', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034191', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034202', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034206', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034217', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034220', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034221', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034232', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034236', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034247', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034250', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034251', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034262', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034265', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034266', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034277', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034280', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034281', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034292', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034295', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034296', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034307', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034310', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034311', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034322', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034325', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034326', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034337', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034340', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034341', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034352', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034355', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034356', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034370', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034371', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034382', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034385', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034386', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034397', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034401', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034412', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034415', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034416', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034427', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034430', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034431', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034442', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034445', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034446', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034457', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034460', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034461', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034472', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034475', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034476', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034487', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034490', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034491', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034502', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034505', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034506', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034517', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034520', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034521', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034532', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034535', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034536', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034547', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034367', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034205', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034127', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034085', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034067', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034055', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034052', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034400', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034235', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034146', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034101', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034082', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034070', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034056', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1123 | Q34 | What are the names of the genes that are targeted by the drug Binimetinib in the treatment of cutaneous melanoma? | In the context of cutaneous melanoma, the drug Binimetinib targets the gene mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cutaneous melanoma%" OR LOWER(efo_term) LIKE "%cutaneous melanoma%") AND (LOWER(drugName) LIKE "%binimetinib%" OR LOWER(tradeNames_list) LIKE "%binimetinib%" OR LOWER(syns_list) LIKE "%binimetinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_926782', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926860', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926886', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926912', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926964', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926990', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927016', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927068', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927094', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927120', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927146', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926834', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926730', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926678', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926652', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927042', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926938', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926808', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926756', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926704', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1175 | Q34 | What are the names of the genes that are targeted by the drug Linagliptin in the treatment of type 2 diabetes mellitus? | In the context of type 2 diabetes mellitus, the drug Linagliptin targets the gene dipeptidyl peptidase 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%type 2 diabetes mellitus%" OR LOWER(efo_term) LIKE "%type 2 diabetes mellitus%") AND (LOWER(drugName) LIKE "%linagliptin%" OR LOWER(tradeNames_list) LIKE "%linagliptin%" OR LOWER(syns_list) LIKE "%linagliptin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_932957', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932987', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932997', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933007', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933027', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933037', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932977', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932937', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932917', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932907', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933017', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932967', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932947', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932927', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.474 | Q34 | What are the names of the genes that are targeted by the drug Ephedrine Sulfate in the treatment of Nasal congestion? | In the context of Nasal congestion, the drug Ephedrine Sulfate targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D, adrenoceptor alpha 1B, adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nasal congestion%" OR LOWER(efo_term) LIKE "%nasal congestion%") AND (LOWER(drugName) LIKE "%ephedrine sulfate%" OR LOWER(tradeNames_list) LIKE "%ephedrine sulfate%" OR LOWER(syns_list) LIKE "%ephedrine sulfate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_418285', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_418300', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_418305', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_418310', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_418320', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_418325', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_418330', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_418340', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418345', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418335', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_418295', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_418265', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_418260', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_418275', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_418315', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_418290', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_418280', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_418270', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.978 | Q34 | What are the names of the genes that are targeted by the drug Ribociclib Succinate in the treatment of neoplasm? | In the context of neoplasm, the drug Ribociclib Succinate targets the gene cyclin dependent kinase 4 and cyclin dependent kinase 6. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%ribociclib succinate%" OR LOWER(tradeNames_list) LIKE "%ribociclib succinate%" OR LOWER(syns_list) LIKE "%ribociclib succinate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_848933', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848936', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848937', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848938', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848940', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848941', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848942', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848944', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848945', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848946', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848947', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848949', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848950', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848951', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848952', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848953', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848954', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848955', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848956', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848957', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848958', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848960', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848961', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848962', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848963', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848964', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848966', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848967', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848968', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848969', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848970', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848971', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848972', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848973', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848974', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848975', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848976', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848977', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848978', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848979', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848980', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848981', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848982', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848983', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848984', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848985', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848986', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848987', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848988', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_848989', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_848990', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_848992', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_848993', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_848994', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_848995', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_848996', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_848997', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_848999', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849000', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849001', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849002', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849003', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849004', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849005', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849006', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849007', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849008', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849009', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849010', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849011', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849012', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849013', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849014', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849015', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849016', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849017', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849018', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849019', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849020', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849021', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849022', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849023', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849024', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849025', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849026', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849027', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_848991', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_848959', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848943', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848935', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848931', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848929', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848928', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848998', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_848965', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848948', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848939', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848934', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848932', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_848930', 'drugName': 'Ribociclib Succinate', 'tradeNames_list': "['Kisqali']", 'syns_list': "['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.658 | Q34 | What are the names of the genes that are targeted by the drug Tolvaptan in the treatment of Hyponatremia? | In the context of Hyponatremia, the drug Tolvaptan targets the gene arginine vasopressin receptor 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hyponatremia%" OR LOWER(efo_term) LIKE "%hyponatremia%") AND (LOWER(drugName) LIKE "%tolvaptan%" OR LOWER(tradeNames_list) LIKE "%tolvaptan%" OR LOWER(syns_list) LIKE "%tolvaptan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_695168', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695213', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695228', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695243', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695273', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695288', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695303', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695318', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695198', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695138', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695108', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695093', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695258', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695183', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695153', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695123', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.402 | Q34 | What are the names of the genes that are targeted by the drug Clobetasol Propionate in the treatment of skin disease? | In the context of skin disease, the drug Clobetasol Propionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%skin disease%" OR LOWER(efo_term) LIKE "%skin disease%") AND (LOWER(drugName) LIKE "%clobetasol propionate%" OR LOWER(tradeNames_list) LIKE "%clobetasol propionate%" OR LOWER(syns_list) LIKE "%clobetasol propionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_243530', 'drugName': 'Clobetasol Propionate', 'tradeNames_list': "['Clarelux', 'Clobaderm', 'Clobetasol propionateClobetasol propionate (emollient)', 'Clobex', 'Cormax', 'DermovateDermovate nn', 'Embeline', 'Embeline e', 'Etrivex', 'Impeklo', 'ImpoyzOlux', 'Olux e', 'Temovate', 'Temovate e']", 'syns_list': "['CCI 4725', 'CCI-4725', 'Clobecort amex', 'ClobetasolClobetasol 17-propionate', 'Clobetasol propionate', 'Dovate', 'GR 2/925NSC-758634', 'Psorex']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243590', 'drugName': 'Clobetasol Propionate', 'tradeNames_list': "['Clarelux', 'Clobaderm', 'Clobetasol propionateClobetasol propionate (emollient)', 'Clobex', 'Cormax', 'DermovateDermovate nn', 'Embeline', 'Embeline e', 'Etrivex', 'Impeklo', 'ImpoyzOlux', 'Olux e', 'Temovate', 'Temovate e']", 'syns_list': "['CCI 4725', 'CCI-4725', 'Clobecort amex', 'ClobetasolClobetasol 17-propionate', 'Clobetasol propionate', 'Dovate', 'GR 2/925NSC-758634', 'Psorex']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243610', 'drugName': 'Clobetasol Propionate', 'tradeNames_list': "['Clarelux', 'Clobaderm', 'Clobetasol propionateClobetasol propionate (emollient)', 'Clobex', 'Cormax', 'DermovateDermovate nn', 'Embeline', 'Embeline e', 'Etrivex', 'Impeklo', 'ImpoyzOlux', 'Olux e', 'Temovate', 'Temovate e']", 'syns_list': "['CCI 4725', 'CCI-4725', 'Clobecort amex', 'ClobetasolClobetasol 17-propionate', 'Clobetasol propionate', 'Dovate', 'GR 2/925NSC-758634', 'Psorex']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243630', 'drugName': 'Clobetasol Propionate', 'tradeNames_list': "['Clarelux', 'Clobaderm', 'Clobetasol propionateClobetasol propionate (emollient)', 'Clobex', 'Cormax', 'DermovateDermovate nn', 'Embeline', 'Embeline e', 'Etrivex', 'Impeklo', 'ImpoyzOlux', 'Olux e', 'Temovate', 'Temovate e']", 'syns_list': "['CCI 4725', 'CCI-4725', 'Clobecort amex', 'ClobetasolClobetasol 17-propionate', 'Clobetasol propionate', 'Dovate', 'GR 2/925NSC-758634', 'Psorex']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243670', 'drugName': 'Clobetasol Propionate', 'tradeNames_list': "['Clarelux', 'Clobaderm', 'Clobetasol propionateClobetasol propionate (emollient)', 'Clobex', 'Cormax', 'DermovateDermovate nn', 'Embeline', 'Embeline e', 'Etrivex', 'Impeklo', 'ImpoyzOlux', 'Olux e', 'Temovate', 'Temovate e']", 'syns_list': "['CCI 4725', 'CCI-4725', 'Clobecort amex', 'ClobetasolClobetasol 17-propionate', 'Clobetasol propionate', 'Dovate', 'GR 2/925NSC-758634', 'Psorex']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243690', 'drugName': 'Clobetasol Propionate', 'tradeNames_list': "['Clarelux', 'Clobaderm', 'Clobetasol propionateClobetasol propionate (emollient)', 'Clobex', 'Cormax', 'DermovateDermovate nn', 'Embeline', 'Embeline e', 'Etrivex', 'Impeklo', 'ImpoyzOlux', 'Olux e', 'Temovate', 'Temovate e']", 'syns_list': "['CCI 4725', 'CCI-4725', 'Clobecort amex', 'ClobetasolClobetasol 17-propionate', 'Clobetasol propionate', 'Dovate', 'GR 2/925NSC-758634', 'Psorex']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243710', 'drugName': 'Clobetasol Propionate', 'tradeNames_list': "['Clarelux', 'Clobaderm', 'Clobetasol propionateClobetasol propionate (emollient)', 'Clobex', 'Cormax', 'DermovateDermovate nn', 'Embeline', 'Embeline e', 'Etrivex', 'Impeklo', 'ImpoyzOlux', 'Olux e', 'Temovate', 'Temovate e']", 'syns_list': "['CCI 4725', 'CCI-4725', 'Clobecort amex', 'ClobetasolClobetasol 17-propionate', 'Clobetasol propionate', 'Dovate', 'GR 2/925NSC-758634', 'Psorex']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243730', 'drugName': 'Clobetasol Propionate', 'tradeNames_list': "['Clarelux', 'Clobaderm', 'Clobetasol propionateClobetasol propionate (emollient)', 'Clobex', 'Cormax', 'DermovateDermovate nn', 'Embeline', 'Embeline e', 'Etrivex', 'Impeklo', 'ImpoyzOlux', 'Olux e', 'Temovate', 'Temovate e']", 'syns_list': "['CCI 4725', 'CCI-4725', 'Clobecort amex', 'ClobetasolClobetasol 17-propionate', 'Clobetasol propionate', 'Dovate', 'GR 2/925NSC-758634', 'Psorex']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243570', 'drugName': 'Clobetasol Propionate', 'tradeNames_list': "['Clarelux', 'Clobaderm', 'Clobetasol propionateClobetasol propionate (emollient)', 'Clobex', 'Cormax', 'DermovateDermovate nn', 'Embeline', 'Embeline e', 'Etrivex', 'Impeklo', 'ImpoyzOlux', 'Olux e', 'Temovate', 'Temovate e']", 'syns_list': "['CCI 4725', 'CCI-4725', 'Clobecort amex', 'ClobetasolClobetasol 17-propionate', 'Clobetasol propionate', 'Dovate', 'GR 2/925NSC-758634', 'Psorex']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243490', 'drugName': 'Clobetasol Propionate', 'tradeNames_list': "['Clarelux', 'Clobaderm', 'Clobetasol propionateClobetasol propionate (emollient)', 'Clobex', 'Cormax', 'DermovateDermovate nn', 'Embeline', 'Embeline e', 'Etrivex', 'Impeklo', 'ImpoyzOlux', 'Olux e', 'Temovate', 'Temovate e']", 'syns_list': "['CCI 4725', 'CCI-4725', 'Clobecort amex', 'ClobetasolClobetasol 17-propionate', 'Clobetasol propionate', 'Dovate', 'GR 2/925NSC-758634', 'Psorex']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243450', 'drugName': 'Clobetasol Propionate', 'tradeNames_list': "['Clarelux', 'Clobaderm', 'Clobetasol propionateClobetasol propionate (emollient)', 'Clobex', 'Cormax', 'DermovateDermovate nn', 'Embeline', 'Embeline e', 'Etrivex', 'Impeklo', 'ImpoyzOlux', 'Olux e', 'Temovate', 'Temovate e']", 'syns_list': "['CCI 4725', 'CCI-4725', 'Clobecort amex', 'ClobetasolClobetasol 17-propionate', 'Clobetasol propionate', 'Dovate', 'GR 2/925NSC-758634', 'Psorex']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243430', 'drugName': 'Clobetasol Propionate', 'tradeNames_list': "['Clarelux', 'Clobaderm', 'Clobetasol propionateClobetasol propionate (emollient)', 'Clobex', 'Cormax', 'DermovateDermovate nn', 'Embeline', 'Embeline e', 'Etrivex', 'Impeklo', 'ImpoyzOlux', 'Olux e', 'Temovate', 'Temovate e']", 'syns_list': "['CCI 4725', 'CCI-4725', 'Clobecort amex', 'ClobetasolClobetasol 17-propionate', 'Clobetasol propionate', 'Dovate', 'GR 2/925NSC-758634', 'Psorex']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243650', 'drugName': 'Clobetasol Propionate', 'tradeNames_list': "['Clarelux', 'Clobaderm', 'Clobetasol propionateClobetasol propionate (emollient)', 'Clobex', 'Cormax', 'DermovateDermovate nn', 'Embeline', 'Embeline e', 'Etrivex', 'Impeklo', 'ImpoyzOlux', 'Olux e', 'Temovate', 'Temovate e']", 'syns_list': "['CCI 4725', 'CCI-4725', 'Clobecort amex', 'ClobetasolClobetasol 17-propionate', 'Clobetasol propionate', 'Dovate', 'GR 2/925NSC-758634', 'Psorex']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243550', 'drugName': 'Clobetasol Propionate', 'tradeNames_list': "['Clarelux', 'Clobaderm', 'Clobetasol propionateClobetasol propionate (emollient)', 'Clobex', 'Cormax', 'DermovateDermovate nn', 'Embeline', 'Embeline e', 'Etrivex', 'Impeklo', 'ImpoyzOlux', 'Olux e', 'Temovate', 'Temovate e']", 'syns_list': "['CCI 4725', 'CCI-4725', 'Clobecort amex', 'ClobetasolClobetasol 17-propionate', 'Clobetasol propionate', 'Dovate', 'GR 2/925NSC-758634', 'Psorex']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243510', 'drugName': 'Clobetasol Propionate', 'tradeNames_list': "['Clarelux', 'Clobaderm', 'Clobetasol propionateClobetasol propionate (emollient)', 'Clobex', 'Cormax', 'DermovateDermovate nn', 'Embeline', 'Embeline e', 'Etrivex', 'Impeklo', 'ImpoyzOlux', 'Olux e', 'Temovate', 'Temovate e']", 'syns_list': "['CCI 4725', 'CCI-4725', 'Clobecort amex', 'ClobetasolClobetasol 17-propionate', 'Clobetasol propionate', 'Dovate', 'GR 2/925NSC-758634', 'Psorex']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243470', 'drugName': 'Clobetasol Propionate', 'tradeNames_list': "['Clarelux', 'Clobaderm', 'Clobetasol propionateClobetasol propionate (emollient)', 'Clobex', 'Cormax', 'DermovateDermovate nn', 'Embeline', 'Embeline e', 'Etrivex', 'Impeklo', 'ImpoyzOlux', 'Olux e', 'Temovate', 'Temovate e']", 'syns_list': "['CCI 4725', 'CCI-4725', 'Clobecort amex', 'ClobetasolClobetasol 17-propionate', 'Clobetasol propionate', 'Dovate', 'GR 2/925NSC-758634', 'Psorex']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.515 | Q34 | What are the names of the genes that are targeted by the drug Amantadine Hydrochloride in the treatment of postencephalitic Parkinson disease? | In the context of postencephalitic Parkinson disease, the drug Amantadine Hydrochloride targets the gene glutamate ionotropic receptor NMDA type subunit 1, glutamate ionotropic receptor NMDA type subunit 2A, glutamate ionotropic receptor NMDA type subunit 2B, glutamate ionotropic receptor NMDA type subunit 2D, glutamate ionotropic receptor NMDA type subunit 3B, glutamate ionotropic receptor NMDA type subunit 2C and glutamate ionotropic receptor NMDA type subunit 3A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%postencephalitic parkinson disease%" OR LOWER(efo_term) LIKE "%postencephalitic parkinson disease%") AND (LOWER(drugName) LIKE "%amantadine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%amantadine hydrochloride%" OR LOWER(syns_list) LIKE "%amantadine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_441093', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441135', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441149', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441163', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441191', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441205', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441219', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441247', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441261', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441275', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441289', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441317', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441331', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441345', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441359', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441373', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441387', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441401', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441415', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441429', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441443', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441471', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441485', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441499', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441513', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441527', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441555', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441569', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441583', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441597', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441611', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441625', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441639', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441653', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441667', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441681', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441695', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441709', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441723', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441737', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441751', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441765', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441779', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441793', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441807', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441821', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441835', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441849', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441863', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441877', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441891', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441919', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441933', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441947', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441961', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441975', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441989', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442017', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442031', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442045', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442059', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442073', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442087', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442101', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442115', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442129', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442143', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442157', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442171', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442185', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442199', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442213', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442227', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442241', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442255', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442269', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442283', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442297', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442311', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442325', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442339', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442353', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442367', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442381', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442395', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442409', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441905', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441457', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441233', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441121', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441065', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441037', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441023', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442003', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441541', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441303', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441177', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441107', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441079', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441051', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease, Postencephalitic', 'efo_term': 'postencephalitic Parkinson disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.322 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of synovitis? | In the context of synovitis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%synovitis%" OR LOWER(efo_term) LIKE "%synovitis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_226942', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227493', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227512', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227778', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228063', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228082', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228348', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228633', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228652', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228918', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228937', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229222', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229488', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229507', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229773', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229792', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230058', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230077', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230343', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230362', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230628', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230913', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230932', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231198', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231217', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231483', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231768', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231787', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232053', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232072', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232338', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232357', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230647', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228367', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227227', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226657', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226372', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226353', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231502', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229203', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227797', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227208', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226923', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226638', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.20 | Q34 | What are the names of the genes that are targeted by the drug Trazodone Hydrochloride in the treatment of major depressive disorder? | In the context of major depressive disorder, the drug Trazodone Hydrochloride targets the gene 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 2A and solute carrier family 6 member 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%major depressive disorder%" OR LOWER(efo_term) LIKE "%major depressive disorder%") AND (LOWER(drugName) LIKE "%trazodone hydrochloride%" OR LOWER(tradeNames_list) LIKE "%trazodone hydrochloride%" OR LOWER(syns_list) LIKE "%trazodone hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_155417', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155432', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155437', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155442', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155452', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155457', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155462', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155472', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155477', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155482', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155487', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155497', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155502', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155507', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155467', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155427', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155407', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155397', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155392', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155492', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155447', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155422', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155412', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155402', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.689 | Q34 | What are the names of the genes that are targeted by the drug Rivaroxaban in the treatment of thrombotic disease? | In the context of thrombotic disease, the drug Rivaroxaban targets the gene coagulation factor X. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thrombotic disease%" OR LOWER(efo_term) LIKE "%thrombotic disease%") AND (LOWER(drugName) LIKE "%rivaroxaban%" OR LOWER(tradeNames_list) LIKE "%rivaroxaban%" OR LOWER(syns_list) LIKE "%rivaroxaban%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_708859', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708964', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708999', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709034', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709104', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709139', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709174', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709244', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709279', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709314', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709349', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709419', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709454', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709489', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709524', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709559', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709594', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709629', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709664', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709699', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709734', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709804', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709839', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709874', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709909', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709944', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710014', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710049', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710084', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710119', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710154', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710189', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710224', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710259', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710294', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709769', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709209', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708929', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708789', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708719', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708684', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709979', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709384', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709069', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708894', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708824', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708754', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.36 | Q34 | What are the names of the genes that are targeted by the drug Aripiprazole Lauroxil in the treatment of schizophrenia? | In the context of schizophrenia, the drug Aripiprazole Lauroxil targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 2A and 5-hydroxytryptamine receptor 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%schizophrenia%" OR LOWER(efo_term) LIKE "%schizophrenia%") AND (LOWER(drugName) LIKE "%aripiprazole lauroxil%" OR LOWER(tradeNames_list) LIKE "%aripiprazole lauroxil%" OR LOWER(syns_list) LIKE "%aripiprazole lauroxil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_158031', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158049', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158055', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158061', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158073', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158079', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158085', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158097', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158103', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158109', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158115', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158127', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158133', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158139', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158145', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158151', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158157', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158163', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158169', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158175', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158181', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158193', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158199', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158205', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158211', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158217', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158229', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158235', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158241', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158247', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158253', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158259', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158265', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158271', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158277', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158283', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158289', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158295', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158301', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158307', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158313', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158319', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158325', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158331', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158337', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158343', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158349', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158355', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158361', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158367', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158373', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158385', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158391', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158397', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158403', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158409', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158415', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158427', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158433', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158439', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158445', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158451', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158457', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158463', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158469', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158475', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158481', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158487', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158493', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158499', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158505', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158511', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158517', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158523', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158529', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158535', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158541', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158547', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158553', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158559', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158565', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158571', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158577', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158583', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158589', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158595', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158379', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158187', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158091', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158043', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158019', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158007', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158001', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158421', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158223', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158121', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158067', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158037', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158025', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158013', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.908 | Q34 | What are the names of the genes that are targeted by the drug Naproxen in the treatment of rheumatoid arthritis? | In the context of rheumatoid arthritis, the drug Naproxen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rheumatoid arthritis%" OR LOWER(efo_term) LIKE "%rheumatoid arthritis%") AND (LOWER(drugName) LIKE "%naproxen%" OR LOWER(tradeNames_list) LIKE "%naproxen%" OR LOWER(syns_list) LIKE "%naproxen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838129', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838180', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838197', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838214', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838248', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838265', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838282', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838331', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838372', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838413', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838454', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838536', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838577', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838618', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838659', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838700', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838741', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838782', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838823', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838864', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838905', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838987', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839028', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839069', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839110', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839151', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839233', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839274', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839315', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839356', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839397', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839438', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839479', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839520', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839561', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839602', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839643', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839684', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838946', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838299', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838163', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838095', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838061', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838044', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839192', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838495', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838231', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838146', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838112', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838078', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.833 | Q34 | What are the names of the genes that are targeted by the drug Acetaminophen in the treatment of muscle cramp? | In the context of muscle cramp, the drug Acetaminophen targets the gene prostaglandin-endoperoxide synthase 2, prostaglandin-endoperoxide synthase 1, transient receptor potential cation channel subfamily V member 1 and fatty acid amide hydrolase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%muscle cramp%" OR LOWER(efo_term) LIKE "%muscle cramp%") AND (LOWER(drugName) LIKE "%acetaminophen%" OR LOWER(tradeNames_list) LIKE "%acetaminophen%" OR LOWER(syns_list) LIKE "%acetaminophen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_829265', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829580', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829685', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829790', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830000', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830105', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830210', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830420', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830525', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830630', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830735', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830945', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831050', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831155', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831260', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831365', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831470', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831575', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831680', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831785', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831890', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832100', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832205', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832310', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832415', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832520', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832730', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832835', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_831995', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_830315', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829475', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829055', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828845', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828740', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832625', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_830840', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829895', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829370', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829160', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828950', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1780 | Q34 | What are the names of the genes that are targeted by the drug Zoledronic Acid in the treatment of postmenopausal osteoporosis? | In the context of postmenopausal osteoporosis, the drug Zoledronic Acid targets the gene farnesyl diphosphate synthase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%postmenopausal osteoporosis%" OR LOWER(efo_term) LIKE "%postmenopausal osteoporosis%") AND (LOWER(drugName) LIKE "%zoledronic acid%" OR LOWER(tradeNames_list) LIKE "%zoledronic acid%" OR LOWER(syns_list) LIKE "%zoledronic acid%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1099877', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100042', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100097', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100152', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099987', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099767', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099657', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099602', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100207', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099932', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099822', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099712', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.410 | Q34 | What are the names of the genes that are targeted by the drug Prednisolone Acetate in the treatment of anemia? | In the context of anemia, the drug Prednisolone Acetate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%anemia%" OR LOWER(efo_term) LIKE "%anemia%") AND (LOWER(drugName) LIKE "%prednisolone acetate%" OR LOWER(tradeNames_list) LIKE "%prednisolone acetate%" OR LOWER(syns_list) LIKE "%prednisolone acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_243764', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'syns_list': "['NSC-10966', 'Prednisolone 21-acetate', 'Prednisolone AcetatePrednisolone acetate', 'Prednisoloni acetas']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243747', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'syns_list': "['NSC-10966', 'Prednisolone 21-acetate', 'Prednisolone AcetatePrednisolone acetate', 'Prednisoloni acetas']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243798', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'syns_list': "['NSC-10966', 'Prednisolone 21-acetate', 'Prednisolone AcetatePrednisolone acetate', 'Prednisoloni acetas']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243781', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'syns_list': "['NSC-10966', 'Prednisolone 21-acetate', 'Prednisolone AcetatePrednisolone acetate', 'Prednisoloni acetas']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.927 | Q34 | What are the names of the genes that are targeted by the drug Ibuprofen in the treatment of Arthralgia? | In the context of Arthralgia, the drug Ibuprofen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%arthralgia%" OR LOWER(efo_term) LIKE "%arthralgia%") AND (LOWER(drugName) LIKE "%ibuprofen%" OR LOWER(tradeNames_list) LIKE "%ibuprofen%" OR LOWER(syns_list) LIKE "%ibuprofen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_840157', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840394', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840473', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840552', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840710', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840789', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840868', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841026', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841105', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841184', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841263', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841421', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841500', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841579', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841658', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841737', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840947', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840315', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839999', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839841', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839762', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841342', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840631', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840236', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840078', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839920', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.541 | Q34 | What are the names of the genes that are targeted by the drug Azelastine Hydrochloride in the treatment of allergic conjunctivitis? | In the context of allergic conjunctivitis, the drug Azelastine Hydrochloride targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic conjunctivitis%" OR LOWER(efo_term) LIKE "%allergic conjunctivitis%") AND (LOWER(drugName) LIKE "%azelastine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%azelastine hydrochloride%" OR LOWER(syns_list) LIKE "%azelastine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455909', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455933', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455941', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455949', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455893', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455877', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455869', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455925', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455917', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455901', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455885', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.763 | Q34 | What are the names of the genes that are targeted by the drug Fentanyl Citrate in the treatment of cancer? | In the context of cancer, the drug Fentanyl Citrate targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%fentanyl citrate%" OR LOWER(tradeNames_list) LIKE "%fentanyl citrate%" OR LOWER(syns_list) LIKE "%fentanyl citrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_785356', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785389', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785400', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785411', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785433', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785444', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785455', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785477', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785488', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785499', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785510', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785532', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785543', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785554', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785565', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785576', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785587', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785598', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785609', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785620', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785631', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785653', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785664', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785675', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785686', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785642', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785378', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785334', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785312', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785301', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785466', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785521', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785422', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785367', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785345', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785323', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1886 | Q34 | What are the names of the genes that are targeted by the drug Cinacalcet Hydrochloride in the treatment of chronic kidney disease? | In the context of chronic kidney disease, the drug Cinacalcet Hydrochloride targets the gene calcium sensing receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic kidney disease%" OR LOWER(efo_term) LIKE "%chronic kidney disease%") AND (LOWER(drugName) LIKE "%cinacalcet hydrochloride%" OR LOWER(tradeNames_list) LIKE "%cinacalcet hydrochloride%" OR LOWER(syns_list) LIKE "%cinacalcet hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149035', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149015', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149010', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149025', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149030', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149020', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1069 | Q34 | What are the names of the genes that are targeted by the drug Ticagrelor in the treatment of acute coronary syndrome? | In the context of acute coronary syndrome, the drug Ticagrelor targets the gene purinergic receptor P2Y12. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%acute coronary syndrome%" OR LOWER(efo_term) LIKE "%acute coronary syndrome%") AND (LOWER(drugName) LIKE "%ticagrelor%" OR LOWER(tradeNames_list) LIKE "%ticagrelor%" OR LOWER(syns_list) LIKE "%ticagrelor%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_920468', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920546', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920572', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920598', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920650', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920676', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920702', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920754', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920780', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920806', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920832', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920884', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920910', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920936', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920962', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920988', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920728', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920520', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920416', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920364', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920338', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920858', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920624', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920494', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920442', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920390', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1208 | Q34 | What are the names of the genes that are targeted by the drug Albuterol in the treatment of asthma? | In the context of asthma, the drug Albuterol targets the gene adrenoceptor beta 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%asthma%" OR LOWER(efo_term) LIKE "%asthma%") AND (LOWER(drugName) LIKE "%albuterol%" OR LOWER(tradeNames_list) LIKE "%albuterol%" OR LOWER(syns_list) LIKE "%albuterol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_936412', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936205', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936376', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936222', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936212', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936322', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936231', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936214', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936358', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936240', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936447', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936394', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936249', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936474', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936223', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936313', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936258', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936483', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936230', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936331', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936267', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936232', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936349', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936276', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936437', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936239', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936285', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936455', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936241', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936385', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936294', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936456', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936248', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936403', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936303', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936482', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936250', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936311', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936312', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936475', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936257', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936320', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936321', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936491', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936259', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936329', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936330', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936484', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936266', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936338', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936339', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936268', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936347', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936348', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936429', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936275', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936356', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936439', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936277', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936365', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936366', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936438', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936284', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936374', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936375', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936465', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936286', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936383', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936384', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936448', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936293', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936392', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936393', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936464', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936295', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936401', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936402', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936457', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936302', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936410', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936411', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936492', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936304', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936419', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936420', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936500', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936493', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936466', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936446', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936430', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936428', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936421', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936340', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936357', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936367', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936221', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936473', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936213', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936203', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936204', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.247 | Q34 | What are the names of the genes that are targeted by the drug Triamcinolone Acetonide in the treatment of type III hypersensitivity reaction disease? | In the context of type III hypersensitivity reaction disease, the drug Triamcinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%type iii hypersensitivity reaction disease%" OR LOWER(efo_term) LIKE "%type iii hypersensitivity reaction disease%") AND (LOWER(drugName) LIKE "%triamcinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%triamcinolone acetonide%" OR LOWER(syns_list) LIKE "%triamcinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222207', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222337', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222077', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221947', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221882', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222272', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222142', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222012', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1427 | Q34 | What are the names of the genes that are targeted by the drug Nimodipine in the treatment of cardiovascular disease? | In the context of cardiovascular disease, the drug Nimodipine targets the gene calcium voltage-gated channel subunit alpha1 C, calcium voltage-gated channel subunit alpha1 S, calcium voltage-gated channel subunit alpha1 D, calcium voltage-gated channel subunit alpha1 F and nuclear receptor subfamily 3 group C member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiovascular disease%" OR LOWER(efo_term) LIKE "%cardiovascular disease%") AND (LOWER(drugName) LIKE "%nimodipine%" OR LOWER(tradeNames_list) LIKE "%nimodipine%" OR LOWER(syns_list) LIKE "%nimodipine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1043392', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043425', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043436', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043447', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043469', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043480', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043491', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043513', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043524', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043535', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043546', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043568', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043579', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043590', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043601', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1043612', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1043623', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1043634', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1043645', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1043656', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1043502', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043414', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043370', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043348', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043337', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043557', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043458', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043403', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043381', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043359', 'drugName': 'Nimodipine', 'tradeNames_list': "['Nimodipine', 'Nimotop', 'Nymalize']", 'syns_list': "['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'NimodipineNimodipine ap', 'Periplum']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1135 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of lung adenocarcinoma? | Trametinib has not been approved by the FDA as a treatment for lung adenocarcinoma, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%lung adenocarcinoma%" OR LOWER(efo_term) LIKE "%lung adenocarcinoma%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_928683', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928803', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928843', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928883', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928963', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929003', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929043', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929123', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929163', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929203', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929243', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929323', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929363', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929403', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929443', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929483', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929523', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929563', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929603', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929643', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929683', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929763', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929803', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929843', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929883', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929923', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930003', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930043', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930083', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930123', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930163', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930203', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930243', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930283', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930323', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930363', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930403', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930443', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930483', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930523', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930563', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930603', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930643', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930683', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930723', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930763', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930803', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930843', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930883', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930923', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930963', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931043', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931083', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931123', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931163', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931203', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931243', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931323', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931363', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931403', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931443', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931483', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931523', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931563', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931603', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931643', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931683', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931723', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931763', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931803', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931843', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931883', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931923', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931963', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932003', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932043', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932083', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932123', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932163', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932203', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932243', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932283', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932323', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932363', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932403', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932443', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931003', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929723', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929083', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928763', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928603', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928523', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928483', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_931283', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929963', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929283', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928923', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928723', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928643', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928563', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Adenocarcinoma of Lung', 'efo_term': 'lung adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.790 | Q34 | What are the names of the genes that are targeted by the drug Olaparib in the treatment of ovarian cancer? | In the context of ovarian cancer, the drug Olaparib targets the gene poly(ADP-ribose) polymerase 2, poly(ADP-ribose) polymerase 1 and poly(ADP-ribose) polymerase family member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ovarian cancer%" OR LOWER(efo_term) LIKE "%ovarian cancer%") AND (LOWER(drugName) LIKE "%olaparib%" OR LOWER(tradeNames_list) LIKE "%olaparib%" OR LOWER(syns_list) LIKE "%olaparib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_800418', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797403', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_799346', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797939', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796733', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_801021', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797001', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797269', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798810', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797537', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_799480', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_799815', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798073', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_800686', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796666', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_800753', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796800', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_801155', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796934', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_801222', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797068', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797202', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798542', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797336', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798944', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797470', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797604', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_799748', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797738', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_799547', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797872', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_799949', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798006', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_800016', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798140', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_800954', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798274', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_800619', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795393', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_800887', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795862', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_800820', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795192', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_801490', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795929', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_801088', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795460', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_801423', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795996', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_801356', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_801289', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796063', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798408', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795527', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798676', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796130', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798609', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_799212', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796197', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798877', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795594', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_799145', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796264', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_799078', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795125', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_800284', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796331', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_799413', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795661', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_799681', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796398', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_799614', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795326', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_800217', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796465', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_799882', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795728', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_800150', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796532', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_800083', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795058', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_801557', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796599', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_800485', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795795', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_801691', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_801624', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_800351', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_799279', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798743', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798475', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798341', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797135', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795259', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_799011', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797805', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_800552', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796867', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797671', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798207', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1726 | Q34 | What are the names of the genes that are targeted by the drug Tafamidis in the treatment of amyloidosis? | In the context of amyloidosis, the drug Tafamidis targets the gene transthyretin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%amyloidosis%" OR LOWER(efo_term) LIKE "%amyloidosis%") AND (LOWER(drugName) LIKE "%tafamidis%" OR LOWER(tradeNames_list) LIKE "%tafamidis%" OR LOWER(syns_list) LIKE "%tafamidis%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097605', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097612', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097613', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097616', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097620', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097621', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097625', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'syns_list': "['FX-1006A', 'Tafamidis meglumine']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097630', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'syns_list': "['FX-1006A', 'Tafamidis meglumine']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097631', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'syns_list': "['FX-1006A', 'Tafamidis meglumine']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097635', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'syns_list': "['FX-1006A', 'Tafamidis meglumine']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097636', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'syns_list': "['FX-1006A', 'Tafamidis meglumine']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097641', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'syns_list': "['FX-1006A', 'Tafamidis meglumine']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097626', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'syns_list': "['FX-1006A', 'Tafamidis meglumine']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097609', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097601', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097597', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097596', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097640', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'syns_list': "['FX-1006A', 'Tafamidis meglumine']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097617', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097608', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097604', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097600', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.493 | Q34 | What are the names of the genes that are targeted by the drug Bupropion Hydrobromide in the treatment of unipolar depression? | In the context of unipolar depression, the drug Bupropion Hydrobromide targets the gene solute carrier family 6 member 2 and solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%unipolar depression%" OR LOWER(efo_term) LIKE "%unipolar depression%") AND (LOWER(drugName) LIKE "%bupropion hydrobromide%" OR LOWER(tradeNames_list) LIKE "%bupropion hydrobromide%" OR LOWER(syns_list) LIKE "%bupropion hydrobromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_434149', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434152', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434153', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434154', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434156', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434157', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434158', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434160', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434161', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434162', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434163', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434165', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434166', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434167', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434168', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434169', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434170', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434171', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434172', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434173', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434174', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434176', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434177', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434178', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434179', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434180', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434182', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434183', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434184', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434185', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434186', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434187', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434188', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434189', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434190', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434191', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434192', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434193', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434194', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434195', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434196', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434197', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434198', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434199', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434200', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434201', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434202', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434203', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434204', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434205', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434206', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434208', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434209', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434210', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434211', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434212', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434213', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434215', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434216', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434217', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434218', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434219', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434220', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434221', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434222', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434223', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434224', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434225', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434226', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434227', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434228', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434229', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434230', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434231', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434232', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434233', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434234', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434235', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434236', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434237', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434238', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434239', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434207', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434175', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434159', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434151', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434147', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434145', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434144', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434214', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434181', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434164', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434155', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434150', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434148', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434146', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_list': "['Aplenzin']", 'syns_list': "['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.156 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of Iridocyclitis? | In the context of Iridocyclitis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%iridocyclitis%" OR LOWER(efo_term) LIKE "%iridocyclitis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218662', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219286', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219494', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219702', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220118', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220326', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220534', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220742', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219078', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218246', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217830', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217622', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219910', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218870', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218454', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218038', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.968 | Q34 | What are the names of the genes that are targeted by the drug Ruxolitinib Phosphate in the treatment of primary myelofibrosis? | In the context of primary myelofibrosis, the drug Ruxolitinib Phosphate targets the gene Janus kinase 1 and Janus kinase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%primary myelofibrosis%" OR LOWER(efo_term) LIKE "%primary myelofibrosis%") AND (LOWER(drugName) LIKE "%ruxolitinib phosphate%" OR LOWER(tradeNames_list) LIKE "%ruxolitinib phosphate%" OR LOWER(syns_list) LIKE "%ruxolitinib phosphate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_843654', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843678', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843680', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843691', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843704', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843706', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843717', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843730', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843732', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843743', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843745', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843758', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843769', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843771', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843782', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843784', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843795', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843797', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843808', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843810', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843821', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843834', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843836', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843847', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843849', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843860', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843873', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843875', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843886', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843888', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843899', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843901', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843912', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843914', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843925', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843927', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843938', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843940', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843951', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843953', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843964', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843966', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843977', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843979', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843990', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843992', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844003', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844005', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844016', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844018', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844029', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844042', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844044', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844055', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844057', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844068', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844070', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844083', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844094', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844096', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844107', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844109', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844120', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844122', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844133', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844135', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844146', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844148', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844159', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844161', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844172', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844174', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844185', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844187', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844198', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844200', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844211', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844213', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844224', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844226', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844237', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844239', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844250', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844252', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844263', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844265', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844031', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843823', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843719', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843667', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843641', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843628', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843626', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844081', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843862', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843756', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843693', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843665', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843652', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843639', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.859 | Q34 | What are the names of the genes that are targeted by the drug Aspirin in the treatment of Recurrent thrombophlebitis? | In the context of Recurrent thrombophlebitis, the drug Aspirin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%recurrent thrombophlebitis%" OR LOWER(efo_term) LIKE "%recurrent thrombophlebitis%") AND (LOWER(drugName) LIKE "%aspirin%" OR LOWER(tradeNames_list) LIKE "%aspirin%" OR LOWER(syns_list) LIKE "%aspirin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_834429', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834900', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835057', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835214', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835528', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835685', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835842', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835999', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834743', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834115', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833801', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833644', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835371', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834586', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834272', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833958', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1322 | Q34 | What are the names of the genes that are targeted by the drug Nitric Oxide in the treatment of pulmonary hypertension? | In the context of pulmonary hypertension, the drug Nitric Oxide targets the gene guanylate cyclase 1 soluble subunit beta 1, guanylate cyclase 1 soluble subunit beta 2 (pseudogene), guanylate cyclase 1 soluble subunit alpha 2 and guanylate cyclase 1 soluble subunit alpha 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pulmonary hypertension%" OR LOWER(efo_term) LIKE "%pulmonary hypertension%") AND (LOWER(drugName) LIKE "%nitric oxide%" OR LOWER(tradeNames_list) LIKE "%nitric oxide%" OR LOWER(syns_list) LIKE "%nitric oxide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_974425', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974587', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974641', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974695', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974803', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974857', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974911', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975019', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975073', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975127', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975181', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975289', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975343', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975397', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975451', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975505', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975559', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975613', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975667', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975721', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975775', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975883', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975937', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975991', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976045', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976099', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976207', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976261', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976315', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976369', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976423', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976477', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976531', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976585', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976639', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976693', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976747', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976801', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976855', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976909', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976963', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977017', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977071', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977125', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977179', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977233', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977287', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977341', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977395', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977449', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977503', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977611', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977665', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977719', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977773', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977827', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977881', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977989', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_978043', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978097', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978151', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978205', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978259', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978313', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978367', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978421', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978475', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978529', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978583', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978637', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978691', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978745', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978799', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978853', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978907', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978961', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979015', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979069', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979123', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979177', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979231', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979285', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979339', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979393', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979447', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979501', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_977557', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975829', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974965', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974533', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974317', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974209', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974155', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977935', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976153', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975235', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974749', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974479', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974371', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974263', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.630 | Q34 | What are the names of the genes that are targeted by the drug Sorafenib Tosylate in the treatment of thyroid carcinoma? | In the context of thyroid carcinoma, the drug Sorafenib Tosylate targets the gene kinase insert domain receptor, B-Raf proto-oncogene, serine/threonine kinase, fms related receptor tyrosine kinase 1, fms related receptor tyrosine kinase 3, KIT proto-oncogene, receptor tyrosine kinase, fms related receptor tyrosine kinase 4, platelet derived growth factor receptor beta, Raf-1 proto-oncogene, serine/threonine kinase and ret proto-oncogene. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thyroid carcinoma%" OR LOWER(efo_term) LIKE "%thyroid carcinoma%") AND (LOWER(drugName) LIKE "%sorafenib tosylate%" OR LOWER(tradeNames_list) LIKE "%sorafenib tosylate%" OR LOWER(syns_list) LIKE "%sorafenib tosylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_683539', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684332', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_685188', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_683417', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683297', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683419', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_684395', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684271', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_685310', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_683358', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_685493', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684088', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683661', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685920', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685064', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_683722', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685918', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_684639', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684151', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_685125', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_683480', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_684517', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684576', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683234', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_685369', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683541', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684761', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685613', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683295', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_685552', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683602', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685674', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685005', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684944', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684149', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_685735', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_683663', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685247', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_684273', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_685186', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685127', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685066', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685857', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_683600', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684334', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_683783', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684393', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_685676', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_683785', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684454', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684456', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684515', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684210', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_683846', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_685249', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_684578', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683905', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_685432', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683907', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684698', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684700', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685430', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684759', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685371', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683968', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_685796', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_684822', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684027', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684881', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685554', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684029', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684942', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_683724', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685737', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685003', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685615', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684090', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_685798', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685491', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685308', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_684820', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_683844', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683356', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_684212', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_683236', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_684637', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683966', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684883', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685859', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_683478', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683676', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684164', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_685140', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685201', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_684225', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684286', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_683737', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684347', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_683798', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684408', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Adenocarcinoma, Follicular', 'efo_term': 'follicular thyroid carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.690 | Q34 | What are the names of the genes that are targeted by the drug Edoxaban Tosylate in the treatment of atrial fibrillation? | In the context of atrial fibrillation, the drug Edoxaban Tosylate targets the gene coagulation factor X. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%atrial fibrillation%" OR LOWER(efo_term) LIKE "%atrial fibrillation%") AND (LOWER(drugName) LIKE "%edoxaban tosylate%" OR LOWER(tradeNames_list) LIKE "%edoxaban tosylate%" OR LOWER(syns_list) LIKE "%edoxaban tosylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_710333', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'syns_list': "['DU-176B', 'Edoxaban tosilate', 'Edoxaban tosylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710305', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'syns_list': "['DU-176B', 'Edoxaban tosilate', 'Edoxaban tosylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710298', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'syns_list': "['DU-176B', 'Edoxaban tosilate', 'Edoxaban tosylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710319', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'syns_list': "['DU-176B', 'Edoxaban tosilate', 'Edoxaban tosylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710326', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'syns_list': "['DU-176B', 'Edoxaban tosilate', 'Edoxaban tosylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710312', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'syns_list': "['DU-176B', 'Edoxaban tosilate', 'Edoxaban tosylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1675 | Q34 | What are the names of the genes that are targeted by the drug Febuxostat in the treatment of hyperuricemia? | In the context of hyperuricemia, the drug Febuxostat targets the gene xanthine dehydrogenase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hyperuricemia%" OR LOWER(efo_term) LIKE "%hyperuricemia%") AND (LOWER(drugName) LIKE "%febuxostat%" OR LOWER(tradeNames_list) LIKE "%febuxostat%" OR LOWER(syns_list) LIKE "%febuxostat%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1095561', 'drugName': 'Febuxostat', 'tradeNames_list': "['Adenuric', 'Uloric']", 'syns_list': "['Febuxostat', 'NSC-758874', 'TMX-67']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperuricemia', 'efo_term': 'hyperuricemia', 'approvedSymbol': 'XDH', 'approvedName': 'xanthine dehydrogenase'}, {'UUID': 'DrugTargetsIndication121923_text_1095525', 'drugName': 'Febuxostat', 'tradeNames_list': "['Adenuric', 'Uloric']", 'syns_list': "['Febuxostat', 'NSC-758874', 'TMX-67']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperuricemia', 'efo_term': 'hyperuricemia', 'approvedSymbol': 'XDH', 'approvedName': 'xanthine dehydrogenase'}, {'UUID': 'DrugTargetsIndication121923_text_1095516', 'drugName': 'Febuxostat', 'tradeNames_list': "['Adenuric', 'Uloric']", 'syns_list': "['Febuxostat', 'NSC-758874', 'TMX-67']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperuricemia', 'efo_term': 'hyperuricemia', 'approvedSymbol': 'XDH', 'approvedName': 'xanthine dehydrogenase'}, {'UUID': 'DrugTargetsIndication121923_text_1095543', 'drugName': 'Febuxostat', 'tradeNames_list': "['Adenuric', 'Uloric']", 'syns_list': "['Febuxostat', 'NSC-758874', 'TMX-67']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperuricemia', 'efo_term': 'hyperuricemia', 'approvedSymbol': 'XDH', 'approvedName': 'xanthine dehydrogenase'}, {'UUID': 'DrugTargetsIndication121923_text_1095552', 'drugName': 'Febuxostat', 'tradeNames_list': "['Adenuric', 'Uloric']", 'syns_list': "['Febuxostat', 'NSC-758874', 'TMX-67']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperuricemia', 'efo_term': 'hyperuricemia', 'approvedSymbol': 'XDH', 'approvedName': 'xanthine dehydrogenase'}, {'UUID': 'DrugTargetsIndication121923_text_1095534', 'drugName': 'Febuxostat', 'tradeNames_list': "['Adenuric', 'Uloric']", 'syns_list': "['Febuxostat', 'NSC-758874', 'TMX-67']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperuricemia', 'efo_term': 'hyperuricemia', 'approvedSymbol': 'XDH', 'approvedName': 'xanthine dehydrogenase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.573 | Q34 | What are the names of the genes that are targeted by the drug Lidocaine in the treatment of arthritis? | In the context of arthritis, the drug Lidocaine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%arthritis%" OR LOWER(efo_term) LIKE "%arthritis%") AND (LOWER(drugName) LIKE "%lidocaine%" OR LOWER(tradeNames_list) LIKE "%lidocaine%" OR LOWER(syns_list) LIKE "%lidocaine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_641237', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639751', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_640892', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640211', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639176', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_641352', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639406', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639636', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_640786', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_639866', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_641936', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_641007', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640326', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_642847', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642732', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_641246', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_638477', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_643086', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637902', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_641361', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_638592', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638141', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_640662', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_638707', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_641697', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637796', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638822', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_642166', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_638256', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_642042', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_638937', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_642281', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_638017', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_641016', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_639052', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_642971', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_638371', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_642741', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_639167', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_642962', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637787', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_642856', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_639282', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_643307', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_638486', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_643077', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_639397', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_643201', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_638132', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_643192', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_639512', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638601', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638026', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_639627', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_641476', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637911', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_641131', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641821', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_638716', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_641591', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639857', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_641812', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_638247', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_641706', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639972', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_642511', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_638831', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_641122', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640087', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_642157', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_640901', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_642051', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_640202', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_642502', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_638946', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_642272', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_640317', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_642396', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_638362', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_642387', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_640432', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_643316', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_639061', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_641467', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_640547', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_643431', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643422', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_642617', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_641927', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_641582', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_640671', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640556', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_639521', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639742', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_640777', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640096', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_642626', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_639291', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639981', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640441', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.